Sergei A Grando

Picture of Sergei A Grando
Distinguished Professor, Dermatology
School of Medicine
Distinguished Professor, Biological Chemistry
School of Medicine
Director, Immunobullous Clinic
M.D., Medical Institute, Kyiv, Ukraine, 1980
Ph.D., PostGraduate Institute for Physicians, Kyiv, Ukraine, 1984, Pharmacology and Biochemistry
D.Sc., Central Institute of Dermatology and Venereology, Moscow, Russia, 1989, Immunology and Cell Biology
Phone: (949) 824-2713
Email: sgrando@uci.edu
University of California, Irvine
362 Medical Surge II
Mail Code: 2400
Irvine, CA 92697
Research Interests
Immunobullous Dermatoses, Atopic Dermatitis, Non-neuronal Acetylcholine
Academic Distinctions
2017 Honorary Member, the French Society of Dermatology
2017 America's Most Honored Professionals 2017 - Top 5%
2016 Best of Irvine Award;
2016 Featured in Orange Coast Magazine among Top Doctors chosen by their peers;
2015 Recognized among Castle Connolly Top Doctor for Irvine, CA;
2013-2018 Vice Chair for Research, Department of Dermatology, UC Irvine;
since 2013 Included in Best Doctors in America database;
since 2012 HealthGrades Recognized Doctor;
2010 Doctor of the Year, International Pemphigus and Pemphigoid Foundation, USA
2010-present Vice Chair, Medical Advisory Board of International Pemphigus and Pemphigoid Foundation;
2003-2007 Vice Chair, Dermatology Foundation of California;
2002-present Honorary Member, Ukrainian Association of Dermatologists, Venereologists, Cosmetologists, Ukraine;
2001 2001 Clinical Innovator Award, Flight Attendant Medical Research Institute, USA;
1995 FIRST Award, NIH, NIAMS, USA;
1991-present Honorary Member, Belgian Royal Society of Dermatology and Venereology, Belgium;
1981, 1982, 1983, 1984, 1985, 1986, 1987, 1988 Annual Award for the Best Scientific Presentation among Young Investigators, PostGraduate Institute for Physicians, Kyiv, Ukraine;
1987 Award, Municipal Society for Scientists and Specialists, Kyiv, Ukraine;
1988 Premium, Ukrainian Republican Society for Inventors, Kyiv, Ukraine.
Appointments
2007-present Professor (tenured; Above Scale), Departments of Dermatology (primary), and Biological Chemistry (secondary), University of California Irvine
1996-2007 Professor of Dermatology, Department of Dermatology, University of California Davis
1992-1996 Associate Professor of Dermatology, Department of Dermatology, University of Minnesota,
1991-1992 Visiting Professor, Department of Dermatology, University of Minnesota
1989-1990 Acting Professor, Department of Dermatology and Venereology, PostGraduate Institute for Physicians, Kyiv, Ukraine
1985-1989 Assistant Professor, Department of Dermatology and Venereology, PostGraduate Institute for Physicians, Kyiv, Ukraine
1984-1985 Instructor of Dermatology and Venereology, Department of Dermatology and Venereology, PostGraduate Institute for Physicians, Kyiv, Ukraine
Research Abstract
IMMUNOPATHOPHYSIOLOGY AND DEVELOPMENT OF NON-STEROIDAL TREATMENT OF PEMPHIGUS
Dr. Grando utilized pemphigus patients' IgGs as a probe to identify the pathophysiologically relevant target antigens in the autoimmune blistering disease pemphigus. He found, unexpectedly, that autoantibodies targeted several known as well as novel members of the acetylcholine (ACh) receptor gene superfamilies expressed by skin cells. Later, he has now demonstrated that these receptors control cell shape and intercellular adhesion, and their blockade by auto-antibodies produces cell dysadhesion and blisters. Dr. Grando's lab demonstrated that pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocyte adhesion molecules. He discovered novel mechanisms of targeting cell death and survival and therapeutic action of intravenous IgG (IVIg) in pemphigus. The results indicate that in different pemphigus patients, IgG-induced acantholysis proceeds predominantly via distinct, yet complementary, pathways of programmed cell death and that IVIg protect target cells by up-regulating endogenous caspase and calpain inhibitors. Grando's work in autoimmune pemphigus and paraneoplastic pemphigus has led to the development of non-steroidal therapy for pemphigus and other diseases associated with blistering. He has conducted an IRB-approved clinical trial using a well-tolerated acetylcholinesterase inhibitor, Mestinon, in the treatment of pemphigus patients. The results of his work have altered the way physicians throughout the world understand the mechanisms of pemphigus, and have led directly to the development of new treatment of pemphigus with cholinergic agonist, such as topical application of pilocarpine.


KERATINOCYTE ADHESION AND MIGRATION
The mechanisms mediating and regulating assembly and disassembly of intercellular and cell-substrate junctions is a subject of intensive research. Although functional components of adhesion complexes are well known, much less is known about the signaling mechanisms that initiate, sustain and terminate adhesion and migration. Dr. Grando's research is focused on autocrine/paracrine signaling pathways regulating assembly and disassembly of cell-cell and cell-substrate adhesion complexes in keratinocytes. He has discovered that free cytotransmitter ACh is present in physiologically-relevant concentrations in the skin. Keratinocytes express both the ACh synthesizing and the degrading enzymes, and there is an upward concentration gradient of free ACh in human epidermis. The repertoire of cholinergic enzymes and receptors changes with cell maturation, so that at each stage of their development, keratinocytess respond to ACh via different combinations of nicotinic (nAChRs) and muscarinic (mAChRs) ACh receptors. Keratinocytes can be simultaneously stimulated through two distinct types of cholinergic signaling pathways: 1) the ionic events, generated by opening of ACh-gated ion channels represented by nAChRs; and 2) the metabolic events, elicited due to ACh binding to the G protein-coupled single-subunit transmembrane glycoproteins, or mAChRs. This diversity could allow the single cytotransmitter ACh to exert diverse effects on keratinocytes at various stages of their development, which helps explain a plethora of biological effects of ACh on keratinocytes. Dr. Grando's lab showed that endogenously produced and secreted ACh is essential for maintenance of polygonal cell shape and intercellular junctions by keratinocytes, and that individual subtypes of ACh receptors expressed in these cells produce distinct effects on the adhesive function. Treatment with cholinergic-receptor subtype-preferring drugs, transfection with selective antisense oligonucleotides or small interfering RNA as well as null mutations of the receptor genes led to marked perturbations of cell phenotype and functions maintaining epithelial integrity. Apparently, the regulation of cell adhesion and motility by ACh is more complex then it was originally thought, as it involves multiple signaling pathways downstream of the cholinergic receptor subtypes expressed by the cells. These receptor regulate expression and function of adhesion molecules via signaling pathways involving both kinases and phosphatases. Dr. Grando's research has demonstrated that random migration (chemokinesis) of keratinocytes elicited by nicotinic agonists was predominantly mediated by the signaling events downstream of a3ß2 nAChRs that involved protein kinase C (PKC)-d and the Rho/Rho-associated protein kinase (ROK) pathway. The a7-made nAChR inhibited random migration but facilitated directional migration (chemotaxis). The chemotactic effect of the a7 agonist choline was regulated via the Ca2+-dependent pathway involving Ca2+/calmodulin-dependent protein kinase II (CaMKII), phosphatidylinositol-3-kinase (PI3K) and conventional isoforms of PKC, as well as Rac and Cdc42. New data obtained in Dr. Grando's lab implicated engagement of the Ras/Raf-1/MEK1/ERK pathway in mediating the a7 AChR effects. Dr. Grando's lab also has demonstrated that ACh stimulated keratinocyte chemokinesis through the muscarinic pathway via M4 mAChR, and inhibited it through M3 mAChR. The M4 effects resulted from inhibition of the inhibitory pathway adenylyl cyclase/cAMP/protein kinase A. The M3 effects were mediated through the intracellular Ca2+-dependent guanylyl cyclase/cGMP/protein kinase G signaling upstream from the Rho/ROK pathway. The opposing mechanistic effects of M3 and M4 were accompanied by their reciprocal actions on the expression levels of specific integrin receptors.

CHOLINERGIC EFFECTS OF TOBACCO PRODUCTS IN NON-NEURONAL TISSUES
Dr. Grando's research has demonstrated that in addition to a well-formulated role of nAChRs in the etiology of addiction to tobacco products, tobacco contributes directly to the tumorigenesis through stimulation of nAChRs in target epithelial cells. His lab has shown that nAChRs can mediate pathobiologic effects of the tobacco and nicotine derivatives on oral keratinocytes. The nitrosamines, just like nicotine, bind to nAChRs and evoke an agonistic response upregulating cell growth. Dr. Grando's research with oral keratinocytes has demonstrated that chronic stimulation of nAChRs with pure nicotine, smokeless tobacco or environmental tobacco smoke can alter normal expression of the ACh receptor genes, providing a positive feedback loop that may lead to aberrant cellular responses to autocrine and paracrine ACh. An increased risk to develop lung as well as head and neck cancers immediately after smoking cessation may, therefore, be related to alterations in the nAChR repertoire in target cells. Carcinogenic nitrosamines activating specific nAChRs may also play a key role in the pathogenesis of cancer by acting as tumor promoters that facilitate the outgrowth of cells with genetic damage (epigenetic effect). This makes pharmacologic modulation of cellular nAChRs a potentially powerful treatment tool for medical conditions caused by tobacco usage. Current goal of Dr. Grando's studies is to integrate structural and functional information about the molecular aspects of ligation of keratinocyte nAChRs by nicotinergic ligands with the knowledge on the cholinergic pathways regulating acquisition and maintenance of the specific cell state by human keratinocytes.
Publications
Books, Book Chapter, and Other Monographs
1. Lamberts A, Yale M, Grando SA, Horvath B, Zillikens D, Jonkman MF. Unmet needs in pemphigoid disease: an international survey amongst patients, clinicians, and researchers. In Lamberts A. Pemphigoid Disease: Insights in the nonbullous variant and disease management. Chapter 8, Rijksuniversiteit, Groningen 2020, pp. 133-144.
2. Amber KT, Shiu J, Ferris K, Grando SA. Role of Intravenous Immunoglobulin in Dermatologic Disorders. In: Yamauchi P. (ed) Biologic and Systemic Agents in Dermatology. Springer International Publishing AG, 2018, Chapter 39, pp. 401-423.
3. Mannering I, Yu Y, Grando SA. Intravenous Immunoglobulin: Dermatologic Uses. In: Gaspari A, Tyring S, Kaplan D. Editors. Clinical and Basic Immunodermatology, 2nd Edition, Springer, 2017 pp. 857-870.
4. Czernik A, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: Paraneoplastic pemphigus revisited. In: D.F Murrell (ed). Blistering Disease: Clinical Features, Pathogenesis, Treatment. Springer-Verlag Berlin Heidelberg, 2015, pp. 286-297.
5. Grando SA. Autoantibodies to mucocutaneous antigens. In: Autoantibodies. 2nd Editions. Elsevier, 2007: 765-780.
6. Grando AA, Grando SA. Medical Ethics (A Textbook). Kyiv: Triumph, 1994, 256 p. (In Russian).
7. Turkevitch Y, Glukhenky BT, Tzhisnetskaya A, Grando SA. AIDS. Epidemiology, Clinical Picture, Diagnostics, Prevention. Kyiv: Ukr.SSR Ministry of Health, 1988, 5 p. (In Russian).
8. Glukhenky BT, Grando SA. Immune-Dependent Dermatoses: Ezcema, Atopic Dermatitis, Autoimmune Pemphigus, Pemphigoids. Kyiv: Zdorovya, 1990, 478 p. (In Russian).
9. Grando SA, Glukhenky BT, Boyko YY, Kutsenko NS, Lastovetskaya GI. Immunofluorescent Diagnostics of Dermatoses. Kyiv: Ukr.SSR Ministry of Health, 1988, 28 p. (In Russian).
10. Glukhenky BT, Grando SA, Boyko YY et al. Reference Book on Medical Cosmetics. Kyiv: Zdorovya, 1989, 1304 p. (In Russian).
11. Grando SA. Pemphigus Vulgaris and Bullous Pemphigoid: Immunopathogenesis and Individualized Treatment of Patients. Kyiv: KSATIP, 1989, 519 p. (In Russian).
12. Grando SA, Glukhenky BT, Kutsenko NS, Lastovetskaya GI, Boyko YY, Kozij LM. Comprehensive Stage-by-Stage Individualized Treatments of Patients with Autoimmune Pemphigus. Kyiv: Ukr.SSR Ministry of Health, 1987, 15 p. (In Russian).
13. Grando SA. Kallikrein-Kinin and Protease Inhibitors in Atopic Dermatitis. Kyiv: KSATIP, 1984, 210 p. (In Russian).
14. Glukhenky BT, Kalyuzhnaya LD, Grando SA, Glukhenkaya AB. Comprehensive Examination and Treatment of the Patients with Atopic Dermatitis. Yiv: Ukr.SSR Ministry of Health, 1982, 13 p. (In Russian).

Original Reports
1. Saeed L, Cox SV, Grando SA. Recalcitrant ocular linear IgA bullous disease in a patient with a history of stage III metastatic melanoma treated with a PD-1 inhibitor. British J Dermatol. (Submitted).
2. Foulad DP, Cirillo N, Grando SA. The role of non-neuronal acetylcholine in the autoimmune blistering disease pemphigus vulgaris. Biology 2023, 12, 354.
3. Brami-Cherrier K, Chernavsky A, You H, Grando SA, Brideau-Andersen A, Sondergaard B. Botulinum Neurotoxin Type A Directly Affects Sebocytes and Modulates Oleic Acid-Induced Lipogenesis. Toxins (Basal). 2022 Oct 15;14(10):708.
4. Hutchinson D, Hosking AM, Hong EM, Grando SA. Mitochondrial autoantibodies and the role of apoptosis in pemphigus vulgaris. Antibodies 2022, 11(3):55.
5. Duan J, Grando C, Liu S, Chernyavsky A, Chen J, Andersen B, Grando SA. The M3 muscarinic acetylcholine receptor promotes epidermal differentiation. J Invest Dermatol. 2022 Jul 20:S0022-202X(22)01665-7.
6. Stetkevich SA, Urso B, Saeed L, Hosking AM, Lee BA, Grando SA, Linden KG. Yellow urticaria: a rare phenomenon. Int J Dermatol. 2023 Apr;62(4):e225-e226.
7. Chernyavsky A, Khylynskyi MM, Patel KG, Grando SA. Chronic exposure to the anti-M3 muscarinic acetylcholine receptor autoantibody in pemphigus vulgaris contributes to disease pathophysiology. J Biol Chem. 2022, 298: 101687.
8. Foulad DP, Rigas M, Piracha F, Gupta M, Nguyen M, Grando SA, Memon S. Transient lymphadenopathy during intravenous immunoglobulin (IVIg) in a patient with pemphigus vulgaris. Clin Case Rep. 2021 Sep 15;9(9):e04763.
9. Gualtieri B, Marzano AV, Grando S. Atypical pemphigus: autoimmunity against desmocollins and other non-desmoglein autoantigens. Ital J Dermatol Venerol. 2021, 156:134-141.
10. Grando SA, Rigas M, Chernyavsky A. Rationale for including intravenous immunoglobulin in the multidrug protocol of the curative treatment of pemphigus vulgaris and development of an assay predicting a disease relapse. Int Immunopharmacol 2020, 82:106385.
11. Pavlou P, Antoniadou I, Peraki A, Vitsos A, Dallas P, Ioannou E, Roussis V, Deliconstantinos G, Grando SA, Rallis M. Protective effects of Pinus halepensis Bark Extract and Nicotine on Cigarette Smoke-induced Oxidative Stress in Keratinocytes. In Vivo 2020; 34:1835-1843.
12. Chernyavsky A, Patel KG, Grando SA. Mechanisms of synergy of autoantibodies to M3 muscarinic acetylcholine receptor and secretory pathway CA2+/Mn2+-ATPase isoform 1 in patients with non-desmoglein pemphigus vulgaris. Int Immunopharmacol. 2020, 80:106149.
13. Wang C, Kraus CN, Patel K, Ganesan A, Grando SA. The “real-world” experience of dupilumab treatment of atopic dermatitis in adults: retrospective analysis of patients’ charts. Int J Dermatol. 2020; 59:253-256.
14. Grando SA, Kawashima K, Wessler I: A historic perspective on the current progress in elucidation of the biologic significance of non-neuronal acetylcholine. Int Immunopharmacol 2020, 81:106289.
15. Murrell DF, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz LA, Sinha AA, Payne AS, Daneshpazhooh M, Eming R, Jonkman MF, Mimouni D, Borradori L, Kim SC, Yamagami J, Lehman JS, Saleh MA, Culton DA, Czernik A, Zone JJ, Fivenson D, Ujiie H, Wozniak K, Akman-Karakas A, Bernard P, Korman NJ, Caux F, Drenovska K, Prost-Squarcioni C, Vassileva S, Feldman RJ, Cardones AR, Bauer J, Ioannides D, Jedlickova H, Palisson F, Patsatsi A, Uzun S, Yayli S, Zillikens D, Amagai M, Hertl M, Schmidt E, Aoki V, Grando SA, Shimizu H, Baum S, Cianchini G, Feliciani C, Iranzo P, Mascaro KM Jr., Kowalewski C, Hall R, Groves R, Harman KE, Marinkovich MP, Maverakis E, Werth VP. Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. J Am Acad Dermatol. 2020; 82: 575-585.
16. Kneiber , Kolewalski E, Kridin K, Yale M, Grando DA, Amber K. Gastrointestinal symptoms, gastrointestinal bleeding, and the role of diet in patients with autoimmune blistering disease: A survey of the International Pemphigus and Pemphigoid Foundation. J Eur Acad Dermatol Venereol. 2019; 33: 1935-1940.
17. Chernyavsky AI, Amber KT, Agnoletti AF, Wang C, Grando SA. Synergy among non-desmoglein antibodies contributes to the immunopathology of desmoglein antibody-negative pemphigus vulgaris. J Biol Chem 2019; 294: 4520-4528.
18. Lamberts A, Yale M, Grando SA, Horvath B, Zillikens D, Jonkman MF. Unmet needs in pemphigoid diseases: an international survey amongst patients, clinicians, and researchers. Acta Dermatol Venereol 2019; 99: 224-225.
19. Grando SA. Restrospective analysis of single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs. Int J Dermatol 2019; 58:114-125.
20. Amber KT, Chernyavsky , Agnoletti AF, Cozzani E, Grando SA. Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil derived neurotoxin on human keratinocytes. Exp Dermatol 2018; 27:1322-1327.
21. Hosking AM, Elsensohn A, Makdisi J, Grando SA, de Feraudy S. Keratosis pilaris reubra with muscin deposition. J Cutan Pathol. 2018; 45: 985-961.
22. Amber KT, Valdebran M, Grando SA. Paraneoplastic autoimmune multiorgan syndrome (PAMS): beyond the single phenotype of paraneoplastic pemphigus. Autoimmunity Reviews 2018; 17: 1002-1010.
23. Amber KT, Grando SA. Gastrointestinal prophylaxis in patients with autoimmune blistering disease treated with corticosteroids: an expert survey. Intl J Dermatol 2018; 57: e125-126.
24. Amber KT, Grando SA. Current practices for the prophylaxis against bone mineral density loss in patients with autoimmune blistering disease treated with corticosteroids: an expert survey. J Eur Acad Dermatol Venereol. 2018; 32: e416-418.
25. Amber KT, Valdebran M, Kridin K, Grando SA. The role of eosinophils in bullous pemphigoid: A developing model of eosinophil pathogenicity in mucocutaneous disease. Frontiers in Medicine. 2018; 5: 201.
26. Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris. Frontiers in Immunology 2018; 9:1190.
27. Grando SA, Zachary CB. The non-neuronal and non-muscular effects of botulinum toxin: A graceful opportunity for a deadly molecule to treat a human disease in the skin and beyond. Br J Dermatol. 2018; 178: 1011-1019.
28. Spindler V, Eming R, Schmidt E, Amagai M, Grando SA, Jonkman MF, Kowalczyk AP, Muller EJ, Payne AS, Pincelli C, Sinha AA, Sprecher E, Zillikens D, Hertl M, Waschke J. Mechanisms Causing Loss of Keratinocyte Cohesion in Pemphigus. J Invest Dermatol 2018; 138: 32-37.
29. Nguyen J, Amber KT, Chapman LW, Grando SA. Pemphigus vulgaris complicated by extensive keloid scarring. Clin Exp Dermatol 2018; 43: 76-77.
30. Schmidt E, Spindler V, Eming R, Amagai M, Antonicelli F, Baines J, Belheouane M, ernard P, Borradori L, Caproni M, Di Zenzo G, Grando S, Harman K, Jonkman MF, Koga H, Ludwig R, Kowalczyk AP, Muller E, Nishie W, Pas H, Payne A, Sadik CD, Seppanen A, Setterfield J, Shimizu H, Sinha AA, Sprecher E, Sticherling M, Ujiie H, Yoshida K, Zillikens D, Hertl M, Waschke J. Meeting report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. J Invest Dermatol. 2017; 137: 1199-1203.
31. Amber KT, Korta DZ, de Feraudy S, Grando SA. Vesiculobullous eruption in a patient receiving PUVA treatment for prurigo nodules: A case of PUVA-aggravated pemphigoid nodularis and literature review. Clin Exp Dermatol. 2017, 42: 833-835.
32. Valdebran M, Amber K, Grando SA. Cicatricial (mucous membrane) pemphigoid. Medscape Drugs & Diseases. Updates 05.03.2017. Available at: https://authoring.medscape.com/content/1062534
33. Amber KT, Panganiban CM, Korta D, de Feraudy S, Kelly KM, Grando SA. A case report of bullous pemphigoid associated with melanoma and a review of literature. Melanoma Research 2017; 27: 65-67.
34. Ahmed AR, Carrozzo M, Caux F, Cirillo N, Dmochowski M, Espana A, Gniadecki R, Hertl M, Lopez-Zabalza MJ, Lotti R, Pincelli C, Pittelkow M, Schmidt E, Sinha AA, Sprecher E, Grando SA. Monopathogenic vs. multipathogenic explanations of pemphigus pathophysiology. Exp Dermatol 2016; 25: 839-46.
35. Grando SA, Kawashima K, Kirkpatrick CJ, Kummer W, Wessler I. Recent progress in revealing the biological and medical significance of the non-neuronal cholinergic system. Intl Immunopharmacol. 2015; 29: 1-7.
36. Chen Y, Chernyavsky A, Webber R, Grando SA*, Wang PH* (*co-corresponding, co-senior authors). Critical role of FcRn in the pathogenic action of anti-mitochondrial autoantibodies synergizing with anti-desmoglein autoantibodies in pemphisgus vulgaris. J Bl Chem 2015; 290: 23826-37.
37. Grando SA, Pittelkow M. Pseudo pemphigus phenotypes in mice with inactivated desmoglein 3: Further insight to the complexity of pemphigus pathophysiology. Am J Pathol 2015, 185: 3125-7.
38. Chernyavsky A, Shchepotin IB, Grando SA. Mechanisms of growth-promoting and tumor-protecting effects of epithelial nicotinic acetylcholine receptors. Intl Immunopharmacol 2015; 29: 36-44.
39. Grando SA. The mitochondrion is a common target of disease pathophysiology in pemphigus and pemphigoid. Exp Dermatol 2015; 24: 655-6.
40. Chernyavsky A, Chen Y, Wang PH, Grando SA. The mitochondrial nicotinic acetylcholine receptors targeted by pemphigus vulgaris antibodies protect keratinocytes from apoptolysis. Intl Immunopharmacol 2015; 29: 76-80.
41. Chernyavsky A, Galitovskiy V, Grando SA. Molecular mechanisms of synergy of corneal muscarinic and nicotinic acetylcholine receptors in upregulation of E-cadherin expression. Intl Immunopharmacol 2015; 29: 15-20.
42. Kalantari-Dehaghi M, Parnell E, Armand T, Bernard HU, Grando SA. The nicotinic acetylcholine receptor-mediated reciprocal effects of the tobacco nitrosamine NNK and SLURP-1 on human mammary epithelial cells. Intl Immunopharmacol 2015; 29: 99-104.
43. Ky C, Swasdiburta B, Khademi S, Desai S, Grando SA. Efficacy of IVIG monotherapy in patients with cutaneous lupus erythematosus: Results of proof-of-concept study. Dermatology Reports 2015; 7: 5804.
44. Chernyavsky A, Shchepotin IB, Galitovskiy V, Grando SA. Mechanisms of tumor-promoting activities of nicotine: Synergistic effects of cell membrane and mitochondrial nicotinic acetylcholine receptors. BMC Cancer 2015, 15:152.
45. Taylor J, McMillan R, Shephard M, Setterfield J, Ahmed R, Carrozzo M, Grando S, Mignogna M, Kuten-Shorrer M, Musbah T, Elia A, McGowan R, Kerr AR, Greenberg MS, Hodgson T, Sirois D. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120:161-71.
46. McMillan R, Taylor J, Shephard M, Ahmed R, Carrozzo M, Setterfield J, Grando S, Mignogna M, Kuten-Shorrer M, Musbah T, Elia A, McGowan R, Kerr A, Greenberg M, Hodgson T, Sirois D. World Workshop on Oral Medicine VI: A systematic review of the treatment of mucocutaneous pemphigus vulgaris. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120:132-42.
47. He Y, Shimoda M, Ono Y, Bustos Villalobos I, Konia T, Grando SA, Zone KK, Maverakis E. Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab. JAMA Dermatol. 2015; 151: 646-50.
48. Murrell DF, Marinovic B, Caux F, Prost K, Ahmed R, Wozniak K, Amagai M, Bauer J, Beissert S, Borradori L, Culton D, Fairley JA, Fivenson D, Jonkman MF, Marinkovich MP, Woodley D, Zone J, Aoki V, Bernard P, Bruckner-Tuderman L, Cianchini G, Venning V, Diaz L, Eming E, Grando SA, Hall RP, Hashimoto T, Herrero-Gonzalez JE, Hertl M, Joly P, Karpati S, Kim J, Kim SC, Korman NJ, Kowalewski C, Lee SE, Rubenstein DR, Sprecher E, Yancey K, Zambruno G, Zillikens D, Doan S, Daniel BS, Werth VP. Definitions and outcome measures for mucous membrane pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2015; 72: 168-74.
49. Chernyavsky A, Galitovskiy V, Shchepotin IB, Jester JV, Grando SA. The acetylcholine signaling network of corneal epithelium and its role in regulation of random and directional migration of corneal epithelial cells. Invest Ophthalmal Vis Sci2014; 55: 6921-33.
50. Tang W, Kuruvilla SA, Sevrioukov E, Galitovskiy V, Pan ML, Kalantari-Dehaghi M, Grando SA, Mukherjee J. Targeting histone deacetylase in lunch cancer for early diagnosis: 18F-FAHA PET/CT imaging of NNK-treated A/J mice model. American Journal of Nuclear Medicine and Molecule Imaging 2014; 4: 324-32.
51. Chernyavsky AI, Galitovskiy V, Shschepotin IB, Grando SA. Anti-inflammatory effects of the nicotinergic peptides SLURP-1 and SLURP-2 on human intestinal epithelial cells and immunocytes. BioMed Research International 2014; Vol. 2014, Article ID 609086, 7 pages.
52. Grando SA. Connections of nicotine to cancer. Nature Reviews Cancer 2014; 14:419-29.
53. Phillips C, Kalantari-Dehaghi M, Gindi V, Marchenko S, Chernyavsky A, Chun S, Galitovskiy V, Paslin D, Grando SA. Is Grover’s disease an autoimmune dermatosis? Exp Dermatol 2013; 22: 781-4.
54. Galitovskiy V, Sevrioukov E, Corches A, Kuruvilla SK, Pan ML, Kalantari-Dehaghi M, Chernyavsky AI, Mukherjee J, Grando SA. Development of novel approach to diagnostic imaging of lung cancer with 18F-Nifene PET/CT using A/J mice treated with NNK. J Cancer Res Therapy 2013; 1: 128-37.
55. Kalantari-Dehaghi M, Chen Y, Deng W, Chernyavsky A, Marchenko S, Wang P, Grando SA. Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies. J Biol Chem 2013; 288: 16916-25.
56. Grando SA. The urgent need for randomized clinical trail of rituximab in pemphigus. Sci Transl Med https://stm.sciencemag.org/content/5/175/175ra30/reply#scitransmed_el_3004 (March 15, 2013).
57. Kalantari-Dehaghi M, Anhalt GJ, Camilleri MH, Chernyavsky AI, Chun C, Leiferman KM, Felgner PL, Jasinskas A, Leiferman LM, Liang L, Marchenko S, Nakajima-Sasaki R, Pittelkow MR, Zone JJ, Grando SA. Pemphigus vulgaris autoantibody profiling by proteomic technique. PLoS ONE 2013; 8(3): e57587.
58. Cherynavsky AI, Marchenko S, Phillips C, Grando SA. Auto/paracrine nicotinergic peptides regulate cutaneous stress response to wounding. Dermatoendocrinology 2012; 4:324-30.
59. Gordon W, Galitovskiy V, Edwards R, Andersen B, Grando SA. The tobacco carcinogen nitrocamine induces a differential gene expression response in tumor susceptible A/J and resistant C3H mouse lungs. Eur J Cancer 2013;49:3725-33.
60. Grando SA, Kawashima K, Kirkpatrick CJ, Meurs H, Wessler I. The non-neuronal cholinergic system: basic science, therapeutic implications and new susceptible A/J and resistant C3H mouse lungs. Eur J Cancer 2013;49:3725-33.
61. Parnell EA, Calleja-Macias IE, Kalantari M, Grando SA, Bernard HU. Muscarinic cholinergic signaling in cervical cancer cells affects cell motility via ERK1/2 signaling. Life Sci 2012; 91: 1093-1098.
62. Kalantari-Dehaghi M, Bernard HU, Grando SA. Reciprocal effects of NNK and SLURP-1 on oncogene expression in target epithelial cells. Life Sci 2012; 91: 1122-1125.
63. Galitovskiy V, Chernyavsky AI, Edwards RA, Grando SA. Muscle sarcomas and alopecia in A/J mice chronically treated with nicotine. Life Sci 2012; 91: 1109-1112.
64. Stegemann A, Sindrilaru A, Eckes B, del Rey A, Grando SA, Fiebich BL, Scharffetter-Kochanek K, Lugar TA, Bohm M. Tropisetron, a serotonin antagonist, is a novel antifibrotic agent and attenuates collagen synthesis via the a7 nicotinic acetylcholine receptor. Arthritis Rheum. 2013; 65: 792-804.
65. Calleja-Macias I, Osann K, Remedios-Chan M, Barrera-Saldana HA, Guerrero NN, Anton-Culver H, Chikova A, Grando SA, Bernard HU. Association of single nucleotide polymorphisms of nicotinic acetylcholine receptor subunits with cervical neoplasia. Life Sci 2012; 91: 1099-1102.
66. Chikova A, Bernard HU, Shchepotin IB, Grando SA. New associations of the genetic polymorphisms in nicotinic receptor genes with the risk of lung cancer. Life Sci 2012; 91: 1103-1108.
67. Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, Caux F, Marinovic B, Sinha A, Hertl M, Bernard P, Sirois D, Cianchini G, Fairley J, Jonkman M, Pandya A, Rubenstein D, Zillikens D, Payne A, Woodley D, Zambruno G, Aoki V, Pincelli C, Diaz L, Hall RP, Meurer M, Mascaro JM, Schmidt E, Shimizu H, Zone J, Swerlick R, Culton D, Lipozencic J, Bincie B, Bystryn JC, Grando SA, Werth VP. Consensus statement on the definitions and outcome measures for bullous pemphigoid. J Am Acad Dermatol 2012; 66: 479-85.
68. Chernyavsky AI, Kalantari-Dehaghi M, Phillips C, Marchenko S, Grando SA. Novel cholinergic peptides SLURP-1 and -2 regulate epithelialization of cutaneous and oral wounds. Wound Repair Regen 2012;20:103-13.
69. Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity 2012;45:111-8.
70. Grando SA. Pemphigus autoimmunity: Hypotheses and realities. Autoimmunity 2012;45:7-35.
71. Ortiz A, Grando SA. Smoking and the skin. Int J Dermatol 2012; 51:250-62.
72. Cirillo N, Cozzani E, Carrozzo M, Grando SA. Urban legends: pemphigus vulgaris. Oral Diseases 2012;18:442-5.
73. Grando SA. Muscarinic receptor agonists and antagonists: effects on keratinocyte functions. Handb Exp Pharmacol 2012;208:429-50.
74. Craft N, Fox LP, Goldsmith LA, Tharp MD, Czernik A, Grando SA, Bernard JD. Pemphigus erythematosus. Visual Dx. 2011. October release: http://ww.visualdx.com/visualdx/visualdx6/getDiagnosisText.do?moduleId=7&diagnosisId=52321.
75. Chikova A, Grando SA. Naturally occurring variants of human a9 nicotinic receptor differentially affect bronchial cell proliferation and transformation. PLoS ONE 2011;6 (11) e27978.
76. Schultz HY, Diaz LA, irois DA, Werth WP, Grando SA. Generating consensus research goals and treatment strategies for pemphigus and pemphigoid. J Invest Dermatol 2011; 131: 1395-9.
77. Grando SA, Laquer VT, Le HM. Sirolimus for acute pemphigus vulgaris: A case report and discussion of dualistic therapeutic activity allowing both immunosuppression and keratinocyte protection from apoptolysis. J Am Acad Dermatol 2011;65:684-6.
78. Koval L, Lykkhmus O, Tsetlin V, Khruschov A, Magrini E, Viola A, Chernyavsky A, Qian J, Grando S, Komisarenko S, Skok M. Differential involvement of a4ß2, a2 and a9 a10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro. Int J Biochem Cell Biol 2011: 43; 516-524.
79. Galitovskiy V, Qian J, Chernyavsky AI, Marchenko S, Gindi V, Edwards RA, Grando SA. Cytokine-induced alterations of a7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17 vs. Th2-mediated colitis. J Immunol 2011;187:2677-87.
80. Qian J, Galitovskiy V, Chernyavsky AI, Marchenko S, Grando SA. Plasticity of the murine T cell cholinergic receptors and their role in differentiation of naïve CD4 T cells toward the Th1, Th2 and Th17 lineages. Genes Immun 2011;12:222-30.
81. Schepotin IB, Kolesnik OO, Lukashenko AV, Mahmudov DE, Grando SA. Role of a Fast Track Surgery multimodal program in surgical treatment of colorectal cancer. Clinical Oncology 2011;2:16-20.
82. Kalantari-Dehagli M, Molina DM, Farhadieh M, Morrow WJ, Liang X, Felgner PL, Grando SA. New targets of pemphigus vulgaris antibodies identified by protein array technology. Exp Dermatol 2011,20:145-158.
83. Grando SA, Holubar K, Schwartz RA. Jean-Claude Bystryn 1938-2010. An obituary. Exp Dermatol 2011;20:293-6.
84. Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: twenty years after. Int J Dermatol 2011 50:905-14.
85. Chernyavsky AI, Arredondo J, Galitovskiy V, Qian J, Grando SA. Upregulation of nuclear factor-?B expression by SLURP-1 is mediated by a7 nicotinic acetylcholine receptor and involves both ionic events and activation of protein kinases. Am J Physiol: Cell Physiol 2010; 299: C903-C911.
86. Marchenko S, Chernyavsky AI, Arredondo J, Gindi V, Grando SA. Antimitochondrial autoantibodies in pemphigus vulgaris: a missing link in disease pathophysiology. J Biol Chem 2010;285:3695-3704.
87. Chernyavsky AI, Arredondo J, Skok M, Grando M. Auto/paracrine control of inflammatory cytokines by acetylcholine in macrophange-like U937 cells through nicotinic receptors. Int Immunopharm 2010;10:308-315.
88. Arredondo J, Omelchenko D, Chernyavsky AI, Skok M, Qian J, Grando SA. Functional role of the nicotinic arm of the acetylcholine regulatory axis in human B-cell lines. J Exp Pharmacol 2009:1 1-7.
89. Bystryn JC, Grando SA. The cause of acantholysis in pemphigus: Further support for the “Basal Cell Shrinkage” hypothesis. Br J Dermatol 2009;161:702.
90. Pavlou P, Rallis M, Deliconstantinos G, Papaioannou G, Grando SA. In vivo data on the influence of tobacco smoke and UV light on murine skin. Toxicol Ind Health. 2009;25:231-9.
91. Grando SA, urzen H. Cholinergic control of keratinocyte cohesion. In: Pathophysiology of the Desmosome, Eds. N Cirillo, A Lanza and F Gombos, Research Signpost, 2009, pp. 87-104.
92. Grando SA, Bystryn JC, Chernyavsky AI, Frusic-Zlotkin M, Gniadecki R, Milner Y, Pittelkow MR, Pincelli C. Apopolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Exp Dermatol 2009;18:764-70.
93. Chernyavsky AI, Arredondo J, Qian J, Galitovskiy V, Grando SA. Coupling of ionic events to protein kinase signaling cascades upon activation of a7 nicotinic receptor: Cooprtatic eregulation of a2-integrin expression and Rho-kinase activity. J Biol Chem 2009;284:22140-8.
94. Chernyavsky Al, Arredondo J, Galitovskiy V, Qian J, Grando SA: Structure and function of the nicotinic arm of acetylcholine regulatory axis in human leukemic T cells. Int J Immunopathol Pharmacol. 2009, 22:461-72.
95. Hsu DK, Chernyavsky A1, Chen H-Y, Grando SA, Liu F: Endogenous galectin-3 is localized in membrane lipid rafts and regulates migration of dendritic cells. J Invest Dermatol 2009, 129:573-83.
96. Chernyavsky Al, Arredondo J, Putney DJ, Marsh JS, Grando SA: Potential role for epithelial nicotinic receptors in tobacco related oral and lung cancers. J Stomatol Invest 2008, 2:5-14
97. Grando SA: Basic and clinical aspects of non-neuronal acetylcholine: biological and clinical significance of non-canonical ligands of epithelial nicotinic acetylcholine receptors. J Pharmacol Sci 2008, 106;174–9.
98. Michael D, Grando SA: Novel mechanism for therapeutic action of IVIG in autoimmune blistering disorders. In: Nickoloff BJ, Nestle F (eds): Dermatologic Immunity. Current Directions in Autoimmunity, Karger, 2008, vol 18, pp 333-43.
99. Arredondo J, Chernyavsky AI, Pinkerton KE, Jolvsky D, Grando SA: Receptor-mediated tobacco toxicity: Acceleration of sequential expression of ?5 and ?7 nicotinic receptor subunits in oral keratinocytes exposed to cigarette smoke. FASEB J. 2008; 22:1356-68.
100. Chernyavsky AI, Arredondo J, Piser T, Karlsson E, Grando SA: Differential coupling of M1 muscarinic and ?7 nicotinic receptors to inhibition of pemphigus acantholysis. J Biol Chem 2008; 283:3401-8.
101. Chernyavsky AI, Arredondo J, Vetter DE, Grando SA: Central role of ?9 acetylcholine receptor in coordinating keratinocyte adhesion and motility at the initiation of epithelialization. Exp Cell Res 2007;313:3542–3555.
102. Fujii, YX, Fujigaya H, Moriwaki Y, Misawa H, Kasahara T, Grando SA, Kawashima K: Enhanced serum antigen-specific IgG1 and proinflammatory cytokine production in nicotinic acetylcholine receptor ?7 subunit gene knockout mice. J Neuroimmunol 2007;189:69-74.
103. Arredondo J, Chernyavsky AI, Grando SA: Overexpression of SLURP-1 and -2 alleviates the tumorigenic action of tobacco-derived nitrosamine on immortalized oral epithelial cells. Biochem Pharmacol 2007;74:1315–1319
104. Bystryn J-C, Grando SA: Reply. J Am Acad Dermatol 2007;56:891-892.
105. Song P, Sekhon HS, Arredondo J, Sauer D, Duan J, Lupo SL, Gravett C, Mark GP, Grando SA, Spindel ER: Acetylcholine functions as an autocrine growth factor in small cell lung carcinoma via activation of M3 muscarinic receptors. Cancer Res 2007;67:3936-44.
106. Kurzen H, Wessler I, Kirkpatrick CJ, Kawashima K, Grando SA: Extraneuronal cholinergic system of human skin. Horm Metab Res 2007;39:125-35.
107. Grando SA, Kawashima K, Kirkpatrick CJ, Wessler I: Recent progress in understanding the non-neuronal cholinergic system in humans. Life Sciences 2007; 80: 2181-5.
108. Billet SE, Grando SA, Pittelkow MR: Paraneoplastic autoimmune multiorgan syndrome: Review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006;39:617-630.
109. Bschleipfer T, Schukowski K, Weidner W, Grando SA, Schwantes U, Kummer W, Lips KS: Expression and distribution of cholinergic receptors in the human urothelium. Life Sciences 2007; 80: 2303-7.
110. Zarghooni S, Wunsch J, Bodenbenner M, Brüggmann D, Grando SA, Schwantes U, Wess J, Kummer W, Lips KS:Expressionn of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sciences 2007; 80: 2308-13.
111. Biallas S, Wilker S, Lips KS, Kummer W, Grando SA, Padberg W, Grau V: Immunohistochemical detection of nicotinic acetylcholine receptor subunits ??9 and ?10 in rat lung isografts and allografts. Life Sciences 2007; 80: 2286-9.
112. Grau V, Wilker S, Hartmann P, Lips KS, Grando SA, Padberg W, Fehrenbach H, Kummer W. Administration of keratinocyte growth factor (KGF) modulates the pulmonary expression of nicotinic acetylcholine receptor subunits ?7, ?9 and ?10. Life Sciences 2007; 80: 2290-3.
113. Chernyavsky AI, Arredondo J, Kitajima Y, Grando SA: Desmoglein vs. Non-desmoglein Signaling in Pemphigus Acantholysis: characterization of novel signaling pathways downstream of pemphigus vulgaris antigens. J Biol Chem 2007;282:13804-12.
114. Arredondo J, Chernyavsky AI, Grando SA: SLURP-1 and -2 in normal, immortalized and malignant oral keratinocytes. Life Sciences 2007; 80: 2243-7.
115. Grando SA: Pemphigus in the XXI Century: New life to an old story. Autoimmunity 2006;39:521-530.
116. Hasse S, Paus R, Chernyavsky AI, Grando SA: Alterations of hair follicle growth and pigmentation in M4 muscarinic receptor knockout mice. Life Sciences 2007; 80: 2248-52.
117. Orlov MD, Chernyavsky AI, Arredondo J, Grando SA: Synergistic actions of pemphigus vulgaris IgG, Fas-ligand and tumor necrosis factor-? during induction of basal cell shrinkage and acantholysis. Autoimmunity 2006;39:557-562.
118. Arredondo J, Chernyavsky AI, Pinkerton KE, Jolkovsky DL, Grando SA: Receptor-Mediated Tobacco Toxicity: Alterations of the NF-?B expression and activity downstream of ?7 nicotinic receptor in oral keratinocytes. Life Sciences 2007; 80: 2191-4.
119. Amagai M, Kitajima Y, Milner Y, Mahoney M, Gniadetski R, Ahmed AR, Bystryn JC, Hertl M, Pincelli C, Grando SA: Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just "witnesses of disease"? Viewpoint 6, Exp Dermatol 2006; 15: 815-31.
120. Arredondo J, Chernyavsky AI, Jolkovsky, DL, Webber RJ, Grando SA: SLURP-2: A novel cholinergic signaling peptide in human mucocutaneous epithelium. J Cell Physiol 2006;208:238-245
121. Arredondo J, Chernyavsky AI, Pinkerton KE, Jolkovsky DL, Grando SA: Receptor-Mediated Tobacco Toxicity: Cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of ?7 nicotinic receptor in oral keratinocytes. FASEB J 2006; 20: 2093-2101.
122. Arredondo J, Chernyavsky AI, Grando SA: Nicotinic receptors mediate tumorigenic action of tobacco-derived nitrosamines on immortalized oral epithelial cells. Cancer Biol Ther 2006; 5 511-517.
123. Arredondo J, Chernyavsky AI, Grando SA: The nicotinic receptor antagonists abolish pathobiologic effects of tobacco-derived nitrosamines on BEP2D cells. Journal of Cancer Research and Clinical Oncology 2006;132:653-63.
124. Kong J, Grando SA, Li YC: Regulation of interleukin-1 family cytokines interleukin-1?, interleukin-1 receptor antagonist and interleukin-18 by 1,25-Dihydroxyvitamin D3 in primary keratinocytes. J Immunol 2006;176:3780-3787.
125. Lips KS, Konig P, Schatzle K, Pfeil U, Krasteva G, Spies M, Haberberger RV, Grando SA, Kummer W. Coexpression and spatial association of nicotinic acetylcholine receptor subunits ?7 and ?10 in rat sympathetic neurons. J Mol Neurosci. 2006;30:15-6
126. Schwartz RA, Grando SA: Pemphigus exacerbators. Skinmed 2006; 5:109-110.
127. Grando SA: Cholinergic control of epidermal cohesion. Exp Dermatol 2006; 15: 265-282.
128. Lips KC, Brüggmann D, Pfeil U, Vollerthun R, Grando SA, Kummer W: Nicotinic acetylcholine receptors in rat and human placenta. Placenta 2005;26:735-46.
129. Bystryn J-C, Grando SA: A novel explanation for acantholysis in pemphigus vulgaris – the "Basal Cell Shrinkage” hypothesis. J Am Acad Dermatol 2006; 55:513-516.
130. Grando SA, Pittelkow MR, Schallreuter KU: Adrenergic and cholinergic control in cutaneous biology: physiological and clinical significance. J Invest Dermatol 2006;126:1948-65.
131. Arredondo J, Chernyavsky AI, Webber RJ, Grando SA: Biological effects of SLURP-1 on human keratinocytes. J Invest Dermatol 2005;125:1236 –1241.
132. Chernyavsky AI, Arredondo J, Karlsson E, Wessler I, Grando SA: The Ras/Raf-1/MEK1/ERK signaling pathway coupled to integrin expression mediates cholinergic regulation of keratinocyte directional migration. J Biol Chem 2005;280:39220–39228.
133. Arredondo J, Chernyavsky AI, Karaouni A, Grando SA: Novel mechanisms of target cell death and survival, and of IVIg therapeutic action in pemphigus. Am J Pathol 2005; 167: 1531-1544.
134. Wadhera A, Grando SA: Bullous Pemphigoid. Disease-based Module. Physicians' Information and Education Resource (PIER). On-line publication by the American College of Physicians and American Society of Internal Medicine (http://pier.acponline.org/physicians/diseases/d1023/d1023-pdf.html)
135. Arredondo J, Chernyavsky AI, Jolkovsky DL, Marubio LM, Pinkerton KE, Beaudet AL, Grando SA: Novel Mechanism of Nicotine Toxicity: Regulation of Gene Expression through ?3?2 Nicotinic Acetylcholine Receptors in Oral Keratinocytes. Am J Pathol 2005; 166: 597-613.
136. Chernyavsky AI, Arredondo J, Marubio LM, Grando SA: Differential regulation of keratinocyte chemokinesis and chemotaxis through distinct nicotinic receptor subtypes J Cell Sci 2004;117:5665-79.
137. Chernyavsky AI, Arredondo J, Wess J, Karlsson E, Grando SA: Novel signaling pathways mediating reciprocal control of keratinocyte migration and wound epithelialization by M3 and M4 muscarinic receptors. J Cell Biol 2004;166: 261-72.
138. Grando SA: How prednisolone works in pemphigus? Postepy Dermatologii i Alergologii 2004 21: 4-8.
139. Nguyen, VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA: Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol 2004; 140: 327-334.
140. Nguyen VT, Chernyavsky AI, Arredondo J, Bercovich D, Orr-Urtreger A, Vetter DE, Wess J, Beaudet AL, Kitajima Y, Grando SA: Synergistic control of keratinocyte adhesion through muscarinic and nicotinic acetylcholine receptor subtypes. Exp Cell Res 2004; 294: 534-549.
141. Wadhera A, Grando SA: Pemphigus Vulgaris. Disease-based Module. Physicians' Information and Education Resource (PIER). On-line publication by the American College of Physicians and American Society of Internal Medicine (http://pier.acponline.org/physicians/diseases/d618/d618.html).
142. Nguyen VT, Arredondo J, Chernyavsky AI, Kitajima Y, Pittelkow MR, Grando SA: Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocyte adhesion molecules. J Biol Chem 2004;279:2135-2146.
143. Grando SA: New approaches to the treatment of pemphigus. J Invest Derm Symp Proc 2004;9:84-91.
144. Grando SA, Bernhard JD: "First author, second author, et int, and last author": A proposed citation system for biomedical papers. Science Editor 2003;26:122-123.
145. Grando SA, Kawashima K, Wessler I: The non-neuronal cholinergic system in humans. Life Sci 2003;72:2009-2012.
146. Arredondo J, Hall LL, Ndoye A, Nguyen, VT, Chernyavsky AI, Bercovich D, Orr-Urtreger A, Beaudet AL, Grando SA: Central role of fibroblast ?3 nicotinic acetylcholine receptor in mediating cutaneous effects of nicotine. Lab Invest 2003;83:207-225.
147. Chernyavsky A, Nguyen VT, Arredondo J, Wess J, Grando SA: The M4 muscarinic receptor-selective effects on keratinocyte crawling locomotion. Life Sci 2003;72:2069-2073.
148. Nguyen VT, Arredondo J, Chernyavsky A, Kitajima Y, Grando SA: Keratinocyte acetylcholine receptors regulate cell adhesion. Life Sci 2003;72:2081-2085.
149. Grando SA, Grando AA, Glukhenky BT, Doguzov V, Nguyen VT, Holubar K: History and clinical significance of mechanical symptoms in blistering dermatoses. A reappraisal. J Am Acad Dermatol 2003;48:86-92.
150. Grando SA: Mucocutaneous cholinergic system is targeted in mustard-induced vesication. Life Sci 2003;72:2135-2144.
151. Arredondo J, Nguyen VT, Chernyavsky AI, Bercovich D, Orr-Urtreger A, Vetter DE, Beaudet AL, Grando SA: Functional role of ?7 nicotinic receptor in physiological control of cutaneous homeostasis. Life Sci 2003;72:2063-2067.
152. Arredondo J, Hall LL, Ndoye A, Chernyavsky AI, Jolkovsky DL, Grando SA: Muscarinic acetylcholine receptors regulating cell cycle progression are expressed in human gingival keratinocytes. J Periodontal Res 2003;38;79–89.
153. Arredondo J, Nguyen VT, Chernyavsky AI, Bercovich D, Orr-Urtreger A, Kummer W, Lips K, Vetter DE, Grando SA: Central role of ?7 nicotinic receptor in differentiation of the stratified squamous epithelium. J Cell Biol 2002;159:325-336.
154. Arredondo J, Nguyen, VT, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA: A receptor-mediated mechanism of nicotine toxicity in oral keratinocytes. Lab Invest 2001;81:1653-1668.
155. Buchli R, Ndoye A, Arredondo J, Webber RJ, Grando SA: Identification and characterization of muscarinic acetylcholine receptor subtypes expressed in human skin melanocytes. Mol Cell Biochem 2001;228:57-72.
156. Grando SA: Receptor-mediated action of nicotine in human skin. Int J Dermatol 2001;40:691-693
157. Grando SA, Pittelkow MR, Shultz LD, Dmochowski M, Nguyen VT: Pemphigus: an unfolding story. J Invest Dermatol 2001;117:990-995.
158. Nguyen VT, Ndoye A, Hall LL, Zia S, Arredondo J, Chernyavsky AI, Kist DA, Zelickson, BD, Lawry MA, Grando SA: Programmed cell death of keratinocytes in human epidermis culminates in apoptotic secretion of a humectant upon secretagogue action of acetylcholine. J Cell Sci 2001; 114:1189-1204.
159. Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, Webber RJ, Pittelkow MR, Lynch PJ, Grando SA: Classification, clinical manifestations and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome. A reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001;137:193-206.
160. Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA: Antibodies against keratinocyte antigens other than desmoglein 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000;106:1467-1479.
161. Grando SA: Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology (Basel) 2000;201:290-295.
162. Grando SA, Dahl, MV: Nicotine and pemphigus. Arch Dermatol 2000;136;1269.
163. Nguyen VT, Ndoye A, Grando SA: Novel human ?9 acetylcholine receptor regulating keratinocyte adhesion is targeted by pemphigus vulgaris autoimmunity. Am J Pathol 2000;157:1377-1391.
164. Nguyen VT, Ndoye A, Grando SA: Pemphigus vulgaris antibody identifies pemphaxin—a novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 2000;275:29466-29476.
165. Zia S, Ndoye A, Lee TX, Webber RJ, Grando SA: Receptor-mediated inhibition of keratinocyte migration by nicotine involves modulations of calcium influx and intracellular concentration. J Pharm Exp Ther 2000;293:973-981.
166. Nguyen VT, Hall LL, Gallacher G, Ndoye A, Jolkovsky DL, Webber RG, Buchli R, Grando SA: Choline acetyltransferase, acetylcholinesterase, and nicotinic acetylcholine receptors of human gingival and esophageal epithelia. J Dent Res 2000;72:939-949.
167. Buchli R, Ndoye A, Rodriguez JG, Zia S, Webber RJ, Grando SA: Human skin fibroblasts express m2, m4, and m5 subtypes of muscarinic acetylcholine receptors. J Cell Biochem 1999;74:264-277.
168. Ndoye A, Buchli R, Nguyen VT, Zia S, Webber RJ, Lawry MA, Grando SA: Identification and mapping of keratinocyte muscarinic acetylcholine receptor subtypes in human epidermis. J Invest Derm 1998;111:410-416.
169. Nguyen VT, Lee TX, Ndoye A, Shultz LD, Pittelkow MR, Dahl MV, Lynch PJ, Grando SA: The pathophysiological significance of non-desmoglein targets of pemphigus autoimmunity. Pemphigus vulgaris and foliaceus patients develop antibodies against keratinocyte cholinergic receptors. Arch Dermatol 1998;134:971-980.
170. Zia S, Ndoye A, Nguyen VT, Grando SA: Nicotine enhances expression of the ?3, ?4, ?5, and ?7 nicotinic receptors modulating calcium metabolism and regulating adhesion and motility of respiratory epithelial cells. Res Commun Molec Pathol Pharmacol 1997;97:243-262
171. Grando SA: Biological functions of keratinocyte cholinergic receptors. J Invest Dermatol Symp Proc 1997; 2: 41-48.
172. Grando SA, Horton RM: The keratinocyte cholinergic system with acetylcholine as an epidermal cytotransmitter. Curr Opin Dermatol 1997: 4: 262-268.
173. Grando SA, Schofield OMV, Skubitz APN, Kist DA, Zelickson BD, Zachary CB: Nodular basal cell carcinoma in vivo vs. in vitro: Establishment of pure cell cultures, cytomorphologic characteristics, ultrastructure, immunophenotype, biosynthetic activities, and generation of antisera. Arch Dermatol 1996;132:1185-1193.
174. Grando SA, Horton RM, Mauro TM, Kist DA, Dahl MV: Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. J Invest Dermatol 1996; 107:412-418.
175. Grando SA, Horton RM, Pereira EFR, Diethelm-Okita BM, George PM, Albuquerque EX, Conti-Fine BM: A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol 1995;105:774-781.
176. Grando SA, Zelickson BD, Kist DA, Weinshenker D, Bigliardi PL, Wendelschafer-Crabb G, Kennedy WR, Dahl MV: Keratinocyte muscarinic acetylcholine receptors: immunolocalization and partial characterization. J Invest Dermatol, 1995;104:95-100.
177. Conti-Tronconi BM, McLane KE, Raftery MA, Grando SA, Protti MP: The nicotinic acetylcholine receptor: Structure and autoimmune pathology. In: CRC: Critical Reviews in Biochemistry and Molecular Biology, 1994;29:69-123.
178. Dahl MV, Grando SA: Chronic dermatophytosis: What is specific about Trichophyton rubrum? Adv Dermatol, 1994;9:97-109.
179. Grando SA, Crosby AM, Zelickson BD, Dahl MV: Agarose gel keratinocyte outgrowth system as a model of skin re-epithelization: Requirement of endogenous acetylcholine for outgrowth initiation. J Invest Dermatol, 1993;101:804-810.
180. Grando SA, Kist DA, Qi M, Dahl MV: Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol, 1993;101:32-36.
181. Grando SA: Is the keratinocyte cholinergic system altered in pemphigus? Editorial. J Eur Acad Derm Venereol, 1993;2:67-71.
182. Grando SA, Cabrera R, Hostager B, Bigliardi PL, Blake JS, Herron MJ, Dahl MV, Nelson RD: Computerized microassay of keratinocyte cell-substrate attachment and proliferation for assessing net stimulatory, inhibitory and toxic effects of compounds on non-immortalized cell lines. Skin Pharmacol, 1993;6:135-147.
183. Grando SA: Physiology of endocrine skin interrelations. A review. J Am Acad Dermatol, 1993;28:981-992.
184. Grando SA, Dahl MV: Activation of keratinocyte muscarinic acetylcholine receptor reverses pemphigus acantholysis. J Eur Acad Derm Venereol, 1993;2:72-86.
185. Grando SA: Decompensation in proteinase-inhibitor system and application of proteinase inhibitors in pemphigus and pemphigoid. J Dermatol Sci, 1992;4:95-97.
186. Grando SA, Herron MJ, Dahl MV, Nelson RD: Binding and uptake of Trichophyton rubrum mannan by human keratinocytes: a time course study. Acta Derm Venereol, 1992;72:273-276.
187. Grando SA, Hostager BS, Herron MJ, Dahl MV, Nelson RD: Binding of Trichophyton rubrum mannan to human monocytes in vitro. J Invest Dermatol, 1992;98:876-880.
188. Grando SA: Pemphigus vulgaris: humoral and cellular mechanisms of immunopathogenesis. Facts, hypotheses and prospects. Nouv Dermatol, 1991;10:747-756.
189. Grando SA: Development of concepts of etiology, pathogenesis and treatment of pemphigus vulgaris based on the hypothesis of atavistic origin of the disease. Medical Hypotheses, 1991;36:43-52.
190. Grando SA, Terman AK, Stupina AS, Glukhenky BT, Romanenko AB: Ultrastructural study of clinically uninvolved skin of patients with pemphigus vulgaris. Clin Exp Dermatol, 1991;16:359-363.
191. Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Chernyavsky AI, Barabash TM: Pemphigus and pemphigoid epidermocytes interfere with interleukin cascade reactions. J Clin Lab Immunol, 1990;32:137-141.
192. Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Chernyavsky AI, Barabash TM: Pemphigus and pemphigoid epidermocytes interfere with interleukin cascade reactions. J Clin Lab Immunol, 1990;32:137-141.
193. Grando SA, Drannik GN: Role of increased eicosanoid production in enhanced immunosuppressive activity of serum after hemoperfusion. Bull Exp Biol Med (New York), 1990;109:214-216.
194. Grando SA, Vasilyev AN, Kostromin AP: Pemphigus antibodies and shedding snake serum enhance susceptibility of epidermal keratinocytes in natural cytotoxic reactions. Autoimmunity, 1990;8:9-16.
195. Grando SA, Drannik GN, Glukhenky BT, Kostromin AP, Romanenko AB, Chayun OA, Chernyavsky AI: Clinical and laboratory evaluation of hemocarboadsorption in autoimmune bullous dermatoses. Int J Artif Organs, 1990;13:181-188.
196. Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Romanenko AB: The effect of experimental haemocarboadsorption upon activity of mononuclear cells from normal and autoimmune patients. Immunology, 1989;66:138-142.
197. Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Chernyavsky AI: Cytotoxic proteases in blister fluid of pemphigus and pemphigoid patients. Int J Tiss Reac, 1989;11:195-201.
198. Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Boiko YY, Senyuk OF: Autoreactive cytotoxic T lymphocytes in pemphigus and pemphigoid. Autoimmunity, 1989;3:247-260.
199. Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA: Mediators of inflammation in blister fluid from patients with pemphigus vulgaris and bullous pemphigoid. Arch Dermatol, 1989;125:925-930.
200. Grando SA, Drannik GN, Kostromin AP, Glukhenky BT, Chernyavsky AI, Korostash TA: Stimulating effect of pemphigus antibodies upon interleukin inhibitor production by normal human epidermocytes. Immunol Invest, 1989;18:1107-1120.
201. Grando SA: Occurrence of pemphigus vulgaris antigen in shedding snake epidermis. Clin Exp Dermatol, 1989;14:259-260.
202. Grando SA: Fixation of pemphigus vulgaris and foliaceus antibodies in shedding snake epidermis. Dermatologica, 1989;178:8-11.
203. Grando SA, Glukhenky BT, Sokolov OA, Korostash TA, Chernyavsky AI: Antibodies of pemphigus foliaceus patients capable of specific binding with shedding snake epidermal antigen. Med Sci Res, 1988;16:165-166.
204. Grando SA: Fixation of antibodies of patients with pemphigus vulgaris and pemphigus foliaceus in the snake epidermis. Bull Exp Biol Med (New York) 1988;105:564-566.
205. Grando SA, Drannik GN, Kostromin AP, Glukhenky BT, Boiko YY, Korostash TA, Demidov SV, Senyuk OF: Serine proteinase esterolytic activity as an assay of cytotoxic reactions. J Immunol Meth, 1988;113:237-246.
206. Grando SA, Drannik GN, Glukhenky BT, Boyko YY, Kostromin AP, Chernyavsky AI: Interleukin cascade reaction inhibition by supernatants of the cultures of antibody-transformed human basal keratinocytes. Immunol Invest, 1988;17:567-576.
207. Glukhenky BT, Grando SA, Kolyadenko VG, Stepanenko VI, Glukhenkaya GB: History and clinical value of Nikolskiy symptom in diagnostics of bullous dermatoses. Ukr J Dermatol Venereol Cosmetol, 2003: No 4:6-12. (In Russian).
208. Grando SA, Glukhenky BT, Stupina AS, Terman AK: Ultrastructural changes in clinically intact skin of patients with pemphigus vulgaris. Vestnik Dermatologii i Venerologii, 1990, No 8:11-14. (In Russian).
209. Grando SA, Glukhenky BT, Kutsenko NS, Lastovetskaya GI, Boiko YY, Barabash TM, Chernyavsky AI: Simulation of pemphigus vulgaris in guinea pigs. Bulletin Experimentalnoj Biologii i Meditsiny, 1990, No 6:604-606. (In Russian).
210. Glukhenky BT, Grando SA: Immunosuppressors in comprehensive therapy of epidermolysis bullosa, bullous and cicatrical pemphigoids. In: Proceedings of the Y Republican Conference on Dermato-Venereology (Tbilisi), 1985, pp. 30-31. (In Russian).
211. Chernyavsky AI, Grando SA: Excretion of serine proteinases by killer cells in the I phase of cellular cytotoxic reactions. In: Current Problems of Scientific and Practical Dermato-Venereology, (Dnepropetrovsk), 1990, pp. 84-85. (In Russian).
212. Grando SA, Glukhenky BT, Kostromin AP, Boiko YY, Kutsenko NS, Korostash TA: Role of the kallikrein-kinin system components in the pathogenesis of pemphigus and pemphigoid. Voprosy Meditsinskoj Khimii, 1990, No 1:23-27. (In Russian).
213. Grando SA, Glukhenky BT, Barabash TM, Zaslavsky LI, Chernyavsky AI: Pathophysiologic disorders and experimental therapy in pemphigus and pemphigoid. Vestnik Dermatologii i Venerologii, 1990, No 11:4-9. (In Russian).
214. Grando SA, Drannik GN: Importance of the increased eicosanoid production in the appearance of high immunosuppressive activity of serum after hemosorption. Bulletin Experimentalnoj Biologii i Meditsiny, 1990, No 2:172-174. (In Russian).
215. Grando SA, Drannik GN: Epidermocytic factor inhibiting interleukin 1 and interleukin 2 production. Immunologiya, 1990, No 1:70-72. (In Russian).
216. Glukhenky BT, Grando SA: Clinical forms of atopic neurodermatitis. Vestnik Dermatologii i Venerologii, 1990, No 4:37-42. (In Russian).
217. Terman AK, Grando SA, Stupina AS, Glukhenky BT: Early symptoms of skin ultrastructural changes in pemphigus vulgaris. Soyuzmedinform (Moscow), 1989, No 17006, 8 p. (In Russian).
218. Grando SA, Kostromin AP, Korostash TA, Chernyavsky AI, Senyuk OF, Drannik GN: Killer cell activity stimulating factor contained in pemphigus vulgaris blister fluid is not a product of arachidonic acid cyclooxygenase metabolism. Immunologiya, 1989, No 1:69-73. (In Russian).
219. Grando SA, Kostromin AP, Drannik GN, Glukhenky BT, Boiko YY, Korostash TA, Chernyavsky AI: Cytotoxic reaction registration by serine esterase activity. Laboratornoye Delo (VINITI, Moscow), 1989, No 5823, 19 p. (In Russian).
220. Grando SA, Glukhenky BT, Sokolov OA, Kravchenko RS, Gavrilov SV: Phylogenetic and experimental studies on the etiology of pemphigus vulgaris. Vestnik Dermatologii i Venerologii, 1989, No 4:7-9. (In Russian).
221. Grando SA, Glukhenky BT, Kutsenko NS, Lastovetskaya GI, Boyko YY, Barabash TM, Chayun OA: Methods of individualized immunocorrection in bullous dermatoses. Dermatologiya i Venerologiya (Kyiv), 1989, Vol. 24:14-17. (In Russian).
222. Grando SA: Disturbances of interleukin cascade reactions in pemphigus and pemphigoid and methods for their correction. Vestnik Dermatologii i Venerologii, 1989, No 9:10-13. (In Russian).
223. Glukhenky BT, Grando SA, Glukhenkaya AB: Plasmapheresis in combined treatment of patients with atopic dermatitis, dermatitis herpetiformis and pemphigus vulgaris. In: Proceedings of the Y Republican Conference on Dermato-Venereology (Tbilisi), 1985, pp. 24-25. (In Russian).
224. Grando SA, Glukhenky BT, Romanenko AB, Chayun OA, Dolya SV: Mechanism of the therapeutic action of extracorporeal detoxification in autoimmune bullous dermatoses. Vestnik Dermatologii i Venerologii, 1988, No 7:6-11. (In Russian).
225. Grando SA, Gajduk IV: Endocrine status in patients with skin diseases in the course of systemic glucocorticoid therapy. In: Pathology of the Endocrine System (Vinnitza), 1988, pp. 8-9. (In Russian).
226. Grando SA, Kostromin AP, Demidov SA, Korostash TA: Comparative study of immunosuppressive effect of doxycycline and prednisolone in in vitro experiments. Antibiotiki i Khimiotherapiya (VINITI, Moscow), 1988, No 3319, pp 1-14. (In Russian).
227. Grando SA, Glukhenky BT, Kutsenko NS, Lastovetskaya GI, Boiko YY, Kozij LM: Effect of glucocorticoid therapy on the endocrine glands' activity in patients with autoimmune skin diseases. Vrachebnoye Delo, 1988, No 8:86-88. (In Russian).
228. Grando SA, Gajduk IV: Pathogenetic mechanisms of oral cavity mucous membrane damage in patients with lichen ruber planus and pemphigus vulgaris. In: Proceedings of the YI United Scientific & Technical Conference, (Vinnitza), 1988, pp. 33-34. (In Russian).
229. Grando SA: Prolonged immunosuppressive therapy of patients with autoimmune bullous dermatoses. In: Proceedings of the YI Republican Scientific Conference on Immunotherapy, (Kyiv-Voroshilovgrad), 1988, pp. 55-56. (In Russian).
230. Grando SA, Glukhenky BT, Drannik GN, Kostromin AP: Contribution of immune cellular reactions to the pathogenesis of pemphigus vulgaris. Vestnik Dermatologii i Venerologii, 1988, No 5:14-18. (In Russian).
231. Grando SA: Phylogenetic study of pemphigus vulgaris, pemphigus foliaceus and bullous pemphigoid antigens. In: Proceedings of the Annual Meeting of the USSR Academy of Medical Science Scientific Council on Dermatology and Venereology, (Dushanbe), 1988, pp. 177-178. (In Russian).
232. Glukhenky BT, Grando SA: Importance of therapeutic regulation of cellular immunity in treatment of patients with immune-dependent dermatoses. In: Proceedings of the Annual Meeting of the USSR Academy of Medical Science Scientific Council on Dermatology and Venereology, (Dushanbe), 1988, pp. 172-176. (In Russian).
233. Grando SA: Fixation of antibodies from patients with pemphigus vulgaris and pemphigus foliaceus in snake epidermis. Bulletin Experimentalnoj Biologii i Meditsiny, 1988, No 4:469-471. (In Russian).
234. Grando SA: Combined immunosuppressive therapy of autoimmune bullous dermatoses. Sovetskaya Meditsina, 1988, No 2:113-115. (In Russian).
235. Grando SA: Effect of hemosorption on interleukin cascade reactions under clinical and experimental conditions. Soyuzmedinform (Moscow), 1988, No 15630, 20 p. (In Russian).
236. Grando SA: Immuno-biochemical parallels in pemphigus and pemphigoid. Dermatologiya i Venerologiya (Kyiv), 1988, Vol. 23:63-69. (In Russian).
237. Grando SA: Soluble mediators of immunity in lesion focus of pemphigus and pemphigoid patients. Soyuzmedinform (Moscow), 1988, No 15629, 11 p. (In Russian).
238. Grando SA: Immunoregulatory activity of epidermal keratinocytes in norm and autoimmune bullous dermatoses. Soyuzmedinform (Moscow), 1988, No 15631, 23 p. (In Russian).
239. Glukhenky BT, Grando SA: Sorption therapy and immunosuppressors in the treatment of patients with pemphigus vulgaris. Soyuzmedinform (Kyiv), 1988, Vol. 3, 3 p. (In Russian).
240. Grando SA, Glukhenky BT, Kutsenko NS, Boiko YY, Lastovetskaya GI, Barabash TM: The management of patients with bullous and other immune-mediated dermatoses. Soyuzmedinform (Kyiv), 1988, Vol. 2, 3 p. (In Russian).
241. Drannik GN, Senyuk OF, Grando SA: Cell-mediated cytotoxicity in autoimmune bullous dermatoses. Immunologiya, 1988, No 4:68-71. (In Russian).
242. Drannik GN, Montag TS, Grando SA, Pavlenko EP, Senyuk OF, Romanenko AB: Distribution of HLA-antigens in patients with immune-dependent skin diseases. Immunologiya, 1988, No 5:68-70. (In Russian).
243. Kostromin AP, Demidov SV, Grando SA, Korostash TA, Borovok MI: Study of the effect of immunoregulatory medical preparations on cyclic nucleotide level and phosphodiesterase activity in lymphocytes. In: Proceedings of the Y Ukrainian Congress on Biochemistry, (Kyiv), 1987, pp. 22-23. (In Russian).
244. Grando SA, Glukhenky BT, Romanenko AB: Endogenous proteinases and their inhibitors in the pathogenesis of pemphigus vulgaris. Vestnik Dermatologii i Venerologii, 1987, No 8:4-7. (In Russian).
245. Grando SA, Glukhenky BT, Kutsenko NS, Kostromin AP, Demidov SV: Immunopathologic aspects of autoimmune bullous dermatoses. Vrachebnoye Delo, 1987, No 9:94-97. (In Russian).
246. Kostromin AP, Grando SA, Chyornaya IV, Korostash TA: Changes of the activity and cyclic nucleotide levels in lymphocytes under the effect of immunosuppressors. In: Advances in Theoretical and Applied Infectious Immunology, (Moscow), 1987, pp. 62-63. (In Russian).
247. Grando SA, Glukhenkaya AB, Ivanchenko LL, Amalyan VA: The effect of enterosorption on microcirculation indices and clinical picture in itching dermatoses. Vestnik Dermatologii i Venerologii, 1987, No 2:41-44. (In Russian).
248. Grando SA, Gajduk IV: Secondary endocrinopathies in patients with immune-dependent dermatoses subjected to high-dosage hormone therapy. In: Proceedings of the IX Regional Scientific Conference, (Vinnitza), 1987, pp. 15-16. (In Russian).
249. Glukhenky BT, Boiko YY, Kozij LM, Lastovetskaya GI, Kutsenko NS, Grando SA, Choban VI: Comprehensive method for treatment of secondary syphilis. Dermatologiya i Venerologiya (Kyiv), 1987 Vol. 22:93-96. (In Russian).
250. Grando SA, Gajduk IV: Peculiarities of immune homeostasis in patients with pemphigus and lichen ruber planus. In: Proceedings of the Y United Scientific & Technical Conference, (Vinnitza), 1987, pp. 33-35. (In Russian).
251. Glukhenky BT, Grando SA, Kostromin AP, Korostash TA: Determination of cyclic nucleotides in immunocompetent cells in some autoimmune injures of the skin. Vrachebnoye Delo, 1987, No 8:103-104. (In Russian).
252. Glukhenky BT, Drannik GN, Grando SA, Glukhenkaya AB, Ivanchenko LL: Immunoregulatory effect of extracorporeal detoxification in patients with eczema, atopic dermatitis and dermatitis herpetiformis. In: Proceedings of the Annual Meeting of the USSR Academy of Medical Science Scientific Council on Dermatology and Venereology, (Kaunas), 1986, pp. 33-34. (In Russian).
253. Glukhenky BT, Drannik GN, Grando SA, Glukhenkaya AB, Ivanchenko LL, Senyuk OF: Methods of sorption treatment of patients with immune-dependent dermatoses. In: Proceedings of the Annual Meeting of the USSR Academy of Medical Science Scientific Council on Dermatology and Venereology, (Kaunas), 1986, pp. 32-33. (In Russian).
254. Glukhenky BT, Sivatchenko TP, Grando SA, Potzibina VV, Makarov AV, Tkhachuk LP: Functional activity of hypophysis, adrenal cortex, and pancreatic gland in patients with bullous dermatoses in the time course of combined immunosuppressive therapy. Vestnik Dermatologii i Venerologii, 1986, No 10:51-53. (In Russian).
255. Grando SA: Serum protein fraction condition in patients with atopic dermatitis as shown by disc-electrophoresis in polyacrylamide gel. Dermatologiya i Venerologiya (Kyiv), 1985, Vol. 20:30-33. (In Russian).
256. Glukhenky BT, Grando SA: Application of proteinase inhibitors in patients with various clinical and morphological forms of atopic dermatitis. Vestnik Dermatologii i Venerologii, 1985, No 1:53-56. (In Russian).
257. Glukhenky BT, Grando SA: Inhibition of the activity of biologically active substances for arresting fits of acute pruritus in atopic dermatitis. Sovetskaya Meditsina, 1985, No 9:115-117. (In Russian).
258. Glukhenky BT, Kalyuzhnaya LD, Boiko YY, Grando SA, Glukhenkaya AB: Combined examination and treatment of patients with atopic dermatitis. Vestnik Dermatologii i Venerologii, 1984, No 7:20-24. (In Russian).
259. Glukhenky BT, Grando SA, Bogdanovitch SN: Results of short-term alimentary relief in treatment of eczema and neurodermatitis. Vestnik Dermatologii i Venerologii, 1984, No 1:51-53. (In Russian).
260. Glukhenky BT, Grando SA: Application of aminocaproic acid to treatment of the patients with skin itching. Soyuzmedinform (Kyiv), 1984, Vol. 4, 2 p. (In Russian).
261. Glukhenky BT, Grando SA, Glukhenkaya AB: The management of atopic dermatitis Soyuzmedinform (Kyiv), 1984, Vol. 3, 3 p. (In Russian).
262. Glukhenky BT, Grando SA, Glukhenkaya AB: Short-time diet at the first stage of treatment of allergic dermatoses. Soyuzmedinform (Kyiv), 1984, Vol. 2, 3 p. (In Russian).
263. Glukhenky BT, Grando SA, Glukhenkaya AB: Immunoregulatory therapy in the treatment of atopic dermatitis. Soyuzmedinform (Kyiv), 1984, Vol. 1, 3 p. (In Russian).
264. Glukhenky BT, Frishman MP, Lastovetskaya GI, Kalyuzhnaya LD, Kutsenko NS, Kozij LM, Boiko YY, Grando SA: The rapid method for treatment of patients with active syphilis. In: Pathogenesis and treatment of chronic skin and venereal diseases, (Kyiv), pp. 108-116. (In Russian).
265. Grando SA, Glukhenky BT, Glukhenkaya AB: Mechanisms of development of atopic dermatitis and participation of the kinin system components in the pathogenesis of the diseases. A review. Soyuzmedinform (Moscow), 1982, No 5534, 32 p. (In Russian).
266. Grando SA, Glukhenkaya AB: Participation of biologically active substances in pruritus emergence. A review. Soyuzmedinform (Moscow), 1982, No 5533, 7 p. (In Russian).
267. Glukhenky BT, Grando SA: Investigation of the components of kallikrein-kinin system in patients with atopic dermatitis. Vestnik Dermatologii i Venerologii, 1982, No 6:10-12. (In Russian).
268. Grando SA, Glukhenkaya AB, Ivanchenko LL: Results of local application of levamisole in children with atopic dermatitis. Pediatriya, Akusherstvo i Ginekologiya, 1981, No 6:31. (In Ukrainian).
269. Grando SA: Some issues of the pathogenesis of itching dermatoses. Vrachebnoye Delo, 1981, No 3:106-108. (In Russian).
270. Grando SA: Determination of kallikrein-kinin system enzymes in patients with itching dermatoses. In: Proceedings of the 51st Scientific Conference of Erevan Medical Institute, (Erevan), 1980, pp. 162-163. (In Russian).
271. Grando SA: Significance of kinin production inhibition in the treatment of atopic dermatitis. In: Organization of Dermato-Venereologic Aid and Modern Approaches to Diagnostics, Treatment and Prevention of Widely Spread and Severe Professional Dermatoses (Kharkhov), 1980, pp. 161-162. (In Russian).

Abstracts
1. Grando SA: Non-neuronal acetylcholine: a historical overview. In: 5th International Symposium on Non-neuronal Acetylcholine: from bench to bedside. September 27-29, 2019, Hyatt Regency, Long Beach, CA, USA, p. 8.
2. Amber KT, Chernyavsky A, Agnoletti A, Wang C, Grando SA: Pathophysiology of non-desmoglein antibody-negative pemphigus vulgaris. J Invest Dermatol 2019; 139 (Suppl.1): S2, Abstr, #9.
3. Kneiber DB, Kowalski E, Kridin K, Yale M, Grando SA, Amber K: The role of diet in patients with autoimmune blistering disease: A survey of the International Pemphigus and Pemphigoid Foundation. J Invest Dermatol 2019; 139 (Suppl.1): S104, Abstr, #606.
4. Grando SA: Rare variants of bullous autoimmune diseases and their target antigens. EADV 2018; Paris, D1T09.4C
5. Lamberts A, Yale M, Grando SA, HorváthB, Zillikens D, Jonkman MF: Unmet needs in pemphigoid diseases: an international survey amongst patients, clinicians and researchers. International Investigative Dermatology, Orlando, 2018
6. Amber K, Agnoletti AF, Chernyavsky A, Grando S: Eosinophil major basic protein has a concentration-dependent cytotoxic effect on cultured keratinocytes. J Invest Dermatol 2017, 137, A615.
7. Grando SA: The non-neuronal effects of botulinum toxin: A novel paradigm of treating human disease with deadly neurotoxins. In: "Neurotransmitters: non-neuronal functions and therapeutic opportunities", March 26-28, 2018, Orleans, France, p. 18
8. Grando SA: Cutaneous non-neuronal cholinergic system. J Neurochem, 2017, 142 (Suppl. 2): 191.
9. Grando SA: Connections of nicotine to cancer and its influence on cancer treatment. Abstracts of IASLC 17th World Conference of Lung Cancer, December 4-7, 2016, Vienna, Austria. J Thoracic Oncol 2017;12 (S1): S47.
10. Grando SA: Cutaneous non-neuronal cholinergic system. In: The XVth International Symposium on Cholinergic Mechanisms. 16-20 October 2016, Marseille, France, Abstract L19, p.34
11. Grando SA: A pemphigus paradigm: new role for FcRn as a delivery vehicle for autoantibodies to intracellular self-antigens. In: The 10th International Congress on Autoimmunity, Leipzig, Germany, 6-10 April 2016. PS23-Parallel session 23: Autoimmunity In Dermatology. Abstract #173.
12. Chernyavsky A, Galitovskiy V, Jester JV, Grando SA: The acetylcholine signaling network of the corneal epithelium in norm and re-epithelialization of corneal defects. In: ESDR 2014 Satellite Meeting Dermatoendocrinology, September 10, 2014, 09:00-12:30, Copenhagen, p. 5-6.
13. Grando SA, Marchenko S, Galitovskiy V, Chernyavsky A: Synergy of nicotinergic peptides and growth factors in regulation of epidermal barrier repair. In: ESDR 2014 Satellite Meeting Dermatoendocrinology, September 10, 2014, 09:00-12:30, Copenhagen, p. 5.
14. Chernyavsky A, Galitovskiy V, Grando SA: Nicotinic acetylcholine receptor (nAChR)-mediated cooperation of SLURP-2 and pro-epithelialization growth factors. J Invest Dermatol 2014, 134 (Suppl.1):S133 (abstr #760).
15. Grando SA: Modern perspectives on pemphigus autoimmunity and treatment. In: The 4th Annual Meeting of Euro-Asian Association of Dermatovenereologists, April 9-11, Jerusalem, Israel. Program & Book of Abstracts, p.40
16. Grando SA: Current concepts in the pathogenesis of pemphigus vulgaris. In: 9th International Congress on Autoimmunity, Nice, France, March 26-30, PS46 - Autoimmunity in Dermatology, Abstract #331.
17. Grando SA: Role of anti-mitochondrial antibodies in pemphigus autoimmunity. J Clin Cell Immunol 2013, 4, 5:28.
18. Kalantari-Dehaghi M, Anhalt G, Camilleri M, Felgner P, Leiferman K, Pittelkow M, Zone J, Grando S: Pemphigus vulgaris autoantibody profiling by proteomic technique. J Invest Dermatol 2013, 133 (Suppl.1):S20 (abstr #116).
19. Kalantari-Dehaghi M, Chen Y, Deng W, Wang PH, Grando SA: Mechanisms of keratinocyte mitochondrial damage in pemphigus vulgaris. J Invest Dermatol 2013, 133 (Suppl.1):S20 (abstr #115).
20. Stegemann A, Sindrilaru2 A, Grando SA, Scharffetter-Kochanek K, Luger TA, Böhm M: The a7 nicotinic acetylcholine receptor – An emerging target for anti-inflammatory and antifibrotic treatment strategies in dermatology. J Invest Dermatol 2013, 133 (Suppl.1):S19 (abstr #109).
21. Grando SA: Role of non-desmoglein specific autoantibodies in pemphigus. International Pre IID 2013 Meeting on Autoimmune Bullous Diseases, May 6th and 7th, 2013, Luebeck, Germany, p. 16.
22. Chikova A, Grando S. Ethnic-specific polymorphisms in CHRNA3 and CHRNA9 genes. Proc Am Assoc Cancer Res 2013, 54 (abstr. #1331).
23. Grando SA, Galitovskiy V, Chernyavsky AI: Anti-inflammatory activities of endogenous nicotinergic peptides in experimental models of inflammatory bowel disease. Siriraj Med J 2012; 6 (Suppl. 2): 94.
24. Grando S: PAMS - What's new? Programme & Exhibitor Book. 3rd Continental Congress of the International Society of Dermatology. Durban, South Africa, 24-27 October, 2012. p.54.
25. Chikova A, Grando SA: Naturally occurring variants of human ?9 nicotinic receptor differentially affect bronchial cell proliferation and transformation. Proc Am Assoc Cancer Res 2012, 53:265 (abstr. #1084).
26. Kalantari-Dehaghi M, Bernard HU, Grando SA: Reciprocal effects of NNK and SLURP-1 on gene expression in target epithelial cells. Third International Symposium on Non-neuronal Acetylcholine. The Auto/Paracrine Function of Non-neuronal Acetylcholine: Basic Science and Therapeutic Implications. August 24-26, 2011, University of Groningen, The Netherlands, 2011, p. 22.
27. Chikova A, Grando SA: Ethnic-specific polymorphisms in CHRNA3 and CHRNA9 genes. Third International Symposium on Non-neuronal Acetylcholine. The Auto/Paracrine Function of Non-neuronal Acetylcholine: Basic Science and Therapeutic Implications. August 24-26, 2011, University of Groningen, The Netherlands, 2011, p. 20.
28. Galitovskiy V, Edwards RE, Grando SA: Chronic administration of nicotine causes muscle neoplasia in mice. Third International Symposium on Non-neuronal Acetylcholine. The Auto/Paracrine Function of Non-neuronal Acetylcholine: Basic Science and Therapeutic Implications. August 24-26, 2011, University of Groningen, The Netherlands, 2011, p 20.
29. Chikova A, Grando SA: Isoforms of CHRNA9 mRNA and their influence on cellular proliferation and transformation. Third International Symposium on Non-neuronal Acetylcholine. The Auto/Paracrine Function of Non-neuronal Acetylcholine: Basic Science and Therapeutic Implications. August 24-26, 2011, University of Groningen, The Netherlands, 2011, p 17.
30. Chikova A, Bernard HU, Grando SA: Association of the rs8040868 variant of CHRNA3 gene encoding a3 nicotinic receptor subunit with increased risk of lung cancer. Third International Symposium on Non-neuronal Acetylcholine. The Auto/Paracrine Function of Non-neuronal Acetylcholine: Basic Science and Therapeutic Implications. August 24-26, 2011, University of Groningen, The Netherlands, 2011, p. 15.
31. Chernyavsky AI, Kalantari-Dehaghi M, Phillips C, Marchenko S, Grando SA: Regulation of keratinocyte migration and cutaneous wound epithelialization by cholinergic peptides involves modulation of integrin expression. In: 1st UC Irvine SOM Clinical, Basic & Translational Science Festival, May 24, 2011; p. 96.
32. Chernyavsky A, Qian J, Grando S: Upregulation of nuclear factor-?B expression by SLURP-1 via keratinocyte ?7 nicotinic acetylcholine receptor (nAChR) involves both ionic events and activation of protein kinases. In: 1st UC Irvine SOM Clinical, Basic & Translational Science Festival, May 24, 2011; p. 95.
33. Marchenko S, Chernyavsky AI, Arredondo J, Gindi V, Grando SA: Antimitochondrial autoantibodies in pemphigus. In: 1st UC Irvine SOM Clinical, Basic & Translational Science Festival, May 24, 2011; p. 94.
34. Kalantari M, Molina DM, Farhadieh M, Vigil A, Morrow WJ, Liang X, Felgner PL, Grando SA: Partial evaluation of pemphigus vulgaris autoantibody profile using the protein array technology. In: 1st UC Irvine SOM Clinical, Basic & Translational Science Festival, May 24, 2011; p. 93.
35. M. Kalantari-Dehaghi, Anhalt GJ, Camilleri MJ, Leiferman KM, Marchenko S, Pittelkow MR, Zone JJ, Grando SA: Pemphigus vulgaris antibodies target PERP and several other keratinocyte membrane and mitochondrial proteins. In: 1st UC Irvine SOM Clinical, Basic & Translational Science Festival, May 24, 2011; p. 92.
36. Phillips C, Gindi V, Marchenko S, Chernyavsky A, Galitovkiy V, Paslin D, Grando SA: Autoimmune Component of Grover’s Disease. In: 1st UC Irvine SOM Clinical, Basic & Translational Science Festival, May 24, 2011; p. 91.
37. Grando SA: The non-neuronal nicotinergic signaling network. In: Nicotinic acetylcholine receptors. A Wellcome Trust Scientific Conference. 18-21 May, 2011, T11.
38. Chikova AK, Grando SA Possible role of the nicotinic acetylcholine receptor alpha9 in lung cancer. Proc Am Assoc Cancer Res. 2011; 52:916
39. Galitovskiy V, Sevrioukov E, Corches A, Pan ML, Constantinescu C, Grando S, Mukherjee J. 18F-Nifene PET for early diagnosis of lung cancer. J Nucl Med 2011; 52 (Suppl):1578
40. Tang W, Galitovskiy V, Sevrioukov E, Pan ML, Constantinescu C, Grando S, Mukherjee J. 18F-FAHA PET for imaging histone deacetylase in lung cancer. J Nucl Med 2011; 52 (Suppl):411.
41. M. Kalantari-Dehaghi, Anhalt GJ, Camilleri MJ, Leiferman KM, Marchenko S, Pittelkow MR, Zone JJ, Grando SA: Pemphigus vulgaris antibodies target PERP and several other keratinocyte membrane and mitochondrial proteins. J Invest Dermatol 2011;131 (Suppl. 1):S11.
42. Chernyavsky AI, Kalantari-Dehaghi M, Phillips C, Marchenko S, Grando SA: Regulation of keratinocyte migration and cutaneous wound epithelialization by cholinergic peptides involves modulation of integrin expression. J Invest Dermatol 2011;131 (Suppl. 1):S131.
43. Phillips C, Gindi V, Marchenko S, Chernyavsky A, Galitovkiy V, Paslin D, Grando SA: Autoimmune Component of Grover’s Disease. J Invest Dermatol 2011;131 (Suppl. 1):S11.
44. Grando SA: Smoking is not sexy - It makes your skin look old. In: The 9th Anti-aging Medicine World Congress & Medispa. Official Congress Book, 2011, pp. 76-77
45. Grando SA: Anti-tumorigenic effects of small cholinergic peptides of the Ly6 protein family. In: The 3rd International Conference on Drug Discovery & Therapy. Current Medicinal Chemistry (Special Issue, Abstracts), 2011, p. 23.
46. Galitovskiy V, Qian J, Chernyavsky AI, Edwards RA, Grando SA: Opposite effects of nicotine on two different murine models of bowel disease. The 8th UCIrvine Immunology Fair, 2010, p.26.
47. Marchenko S, Chernyavsky A, Grando S: Mechanism of activation of intrinsic apoptotic pathway by pemphigus antibodies. In JC Bystryn Pemphigus & Pemphigoid Meeting: From the Bench to the Bedside, November 5 and 6, 2010, p.11.
48. Kalantari M, Grando S, Felgner P: New targets of pemphigus vulgaris antibodies identified by protein array technology. In JC Bystryn Pemphigus & Pemphigoid Meeting: From the Bench to the Bedside, Bethesda, November 5 and 6, 2010, p.12.
49. Grando SA: Smoking and skin cancers. In 13th World Congress on Cancers of the Skin. Proceedings Book, 2010, p. 43.
50. Kalantari M, Molina DM, Farhadieh M, Vigil A, Morrow WJ, Liang X, Felgner PL, Grando SA: Partial evaluation of pemphigus vulgaris autoantibody profile using the protein array technology. J Invest Dermatol 2010;130 (Suppl. 1):S21.
51. Marchenko S, Chernyavsky AI, Arredondo J, Gindi V, Grando SA: Antimitochondrial autoantibodies in pemphigus vulgaris: a missing link in disease pathophysiology. J Invest Dermatol 2010;130 (Suppl. 1):S7.
52. Chernyavsky A, Qian J, Grando S: Upregulation of nuclear factor-?B expression by SLURP-1 via keratinocyte ?7 nicotinic acetylcholine receptor (nAChR) involves both ionic events and activation of protein kinases. J Invest Dermatol 2010;130 (Suppl. 1):S96.
53. Grando S: Cutaneous cholinergic system: lessons for skin pigmentary system. Pigment Cell & Melanoma Rese 2009, 22:495.
54. Qian J, Galitovskiy V, Chernyavsky AI, Marchenko S, Grando SA: Plasticity of the murine T cell cholinergic receptors and their role in differentiation of CD4 cells toward the Th1 and Th2 lineages. The 7th UCIrvine Immunology Fair, 2009, p.24.
55. Galitovskiy V, Qian J, Chernyavsky AI, Marchenko S, Gindi V, Edwards RA, Grando SA: Possible explanation of the dichotomous effect of nicotine on ulcerative colitis and Crohn's disease: A role for Foxp3 T cells. The 7th UCIrvine Immunology Fair, 2009, p.23.
56. Qian J, Chernyavsky A, Galitovskiy V, Grando S: Plasticity of the T cell cholinergic system. J Invest Dermatol 2009;129 (Suppl. 1):S108.
57. Chernyavsky A, Arredondo J, Grando S: A desmoglein 3 pemphigus antibody signaling. J Invest Dermatol 2009;129 (Suppl. 1):S11.
58. Chernyavsky A, Arredondo J, Qian J, Galitovskiy V, Grando S: Novel mechanism of downstream signaling from keratinocyte nicotinic receptors. J Invest Dermatol 2009;129 (Suppl. 1):S91.
59. Grando SA: The muscarinic receptors in keratinocytes: Signaling pathways and biologic effects. In: Speakers Abstracts, Recent Advances in Muscarinic Receptors, Pharmacology & Therapeutics, An ASPET Colloquium, San Diego, April 4-5, 2008.
60. Grando SA: Clinical and pathophysiological significance of non-desmoglein targets of pemphigus antibodies. In: Post IID2008 Satellite International Meeting on Autoimmune Bullous Diseases, Otsu, Japan, May 17-19, 2008, p.10.
61. Grando SA: Keratinocyte cholinergic system under the stress of skin wounding. In: First International Conference on Environmental Stressors in Biology and Medicine, Siena, Italy, June 4-6, 2008, p.10.
62. Chernyavsky A, Arredondo J, Grando SA: Molecular mechanisms of pro-acantholytic effects of pemphigus autoantibodies and anti-acantholytic effects of cholinergic agonists. The Fifth UCIrvine Immunology Fair, 2007, p.32.
63. Grando SA: Nicotinic receptors alter gene expression in keratinocytes. Flight Attendant Medical Research Institute 2007 Monograph, p. 23.
64. Grau V, Wilker S, Hartmann P, Lips K, Grando SA, Padberg W, Fehrenbach H, Kummer W: Keratinocyte growth factor modulates the cholinergic system of the lung. Am J Respir Crit Care Med 2007; 175: A280.
65. Chernyavsky A, Arredondo J, Grando SA: Signaling through ?9 acetylcholine receptor is critical for initiation of keratinocyte migration. J Invest Dermatol 2007;127 (Supp. 1): S96.
66. Grando SA, Chernyavsky A, Arredondo J, Sato-Nagai M, Kitajima Y: Regulation of phosphorylation status of adhesion molecules in pemphigus. J Invest Dermatol 2007:127 (Supp. 1): S31.
67. Arredondo J, Chernyavsky A, Pinkerton KE, Grando SA: Autoregulation of sequential expression of nicotinic receptor subtypes associated with keratinocyte differentiation. J Invest Dermatol 2007:127 (Supp. 1): S19.
68. Grando SA: Biological and clinical significance of non-neuronal acetylcholine and novel peptide ligands of epithelial nicotinic acetylcholine receptors (nAChR). J Pharmacol Sci. 2007 103 (Suppl. I): 28.
69. Hartmann P, Lips KS, Galvis G, Biallas S, Pfeil U, Fronius M, Clauss W, Grando SA, Grau V, Kummer W. Nicotinic receptors on rat alveolar macrophages dampen ATP-induced increase in cytosolic calcium concentration. In: Program and Abstract Book, Second International Symposium on Non-neuronal Acetylcholine, August 31- September 2, 2006, Mainz, Germany, p. 28.
70. Zarghooni S, Wunsch J, Bodenbenner M, Brüggmann D, Grando SA, Schwantes U, Kummer W, Lips KS: Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. In: Program and Abstract Book, Second International Symposium on Non-neuronal Acetylcholine, August 31- September 2, 2006, Mainz, Germany, p. 26.
71. Grau V, Wilker S, Hartmann P, Lips K, Grando SA, Padberg W, Fehrenbach H, Kummer W: Exogenous keratinocyte growth factor (KGF) modulates the cholinergic system of the lung. In: Program and Abstract Book, Second International Symposium on Non-neuronal Acetylcholine, August 31- September 2, 2006, Mainz, Germany, p. 23.
72. Biallas S, Wilker S, Lips KS, Kummer W, Grando SA, Padberg W, Grau V: Nicotinic acetylcholine receptor subunits alpha-9 and -10 in rat lung isografts and allografts. In: Program and Abstract Book, Second International Symposium on Non-neuronal Acetylcholine, August 31- September 2, 2006, Mainz, Germany, p. 23
73. Chernyavsky A, Arredondo J, Wessler I, Grando SA: Intracellular cholinergic signaling regulating directional migration of keratinocytes. In: Program and Abstract Book, Second International Symposium on Non-neuronal Acetylcholine, August 31- September 2, 2006, Mainz, Germany, p. 17.
74. Arredondo J, Chernyavsky A, Pinkerton KE, Grando SA: Nicotinic receptors mediate nicotine toxicity in keratinocytes by altering gene expression and activity of STAT-3. In: Program and Abstract Book, Second International Symposium on Non-neuronal Acetylcholine, August 31- September 2, 2006, Mainz, Germany, p.16.
75. Grando SA: Biological significance of novel noncononical ligands of epithelial nicotinic receptors. In: Program and Abstract Book, Second International Symposium on Non-neuronal Acetylcholine, August 31- September 2, 2006, Mainz, Germany, p. 9.
76. Bystryn J-C, Grando SA. The "basal cell shrinkage” hypothesis - a new explanation for acantholysis in pemphigus vulgaris. J Invest Dermatol 2006:126;2352.
77. Chernyavsky AI, Grando SA. Characterization of novel signaling pathways downstream of non-desmoglein targets of pathogenic autoantibodies in pemphigus vulgaris. J Invest Dermatol 2006:126;2352
78. Chernyavsky A, Arredondo J, Karlsson E, Wessler I, Grando SA. Cholinergic regulation of keratinocyte directional migration is mediated by the Ras/Raf-1/MEK1/ERK signaling pathway altering integrin expression. J Invest Dermatol 2006: 126 (4) Suppl: 26 (Abstr. #152).
79. Arredondo J, Chernyavsky A, Pinkerton KE, Grando SA: Cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of keratinocyte ?7 nicotinic receptor. J Invest Dermatol 2006: 126 (4) Suppl: 86 (Abstr. #514).
80. Orlov MD, Chernyavsky AI, Arredondo J, Grando SA: Synergistic actions of pemphigus vulgaris (PV) IgG, Fas-ligand (Fas-L) and tumor necrosis factor-? (TNF?) during induction of basal cell shrinkage and acantholysis. J Invest Dermatol 2006:126 (4) Suppl: 10 (Abstr. #59).
81. Grando SA: New approaches to prevent pemphigus acantholysis. J Invest Dermatol 2005:125:1087 (Abstr. #16).
82. Grando SA: Development of nonhormonal treatment of pemphigus. Ukr J Dermatol Venereol Cosmetolol 2005; 18: 153.
83. Hsu DK, Chernyavsky A1, Grando SA, Liu F" Galectin-3 regulates migration of macrophages and cutaneous dendritic cells. J Invest Dermatol 2005;124 (4) Suppl.) A11.
84. Grando SA, Chernyavsky A1, Karaouni A, Arredondo J: Novel mechanisms of keratinocyte death and survival, and of therapeutic action of IVIg in pemphigus. J Invest Dermatol 2005;124 (4) Suppl.) A6.
85. Arredondo J, Chernyavsky A1, Grando SA: Novel signaling peptides in human epidermis. J Invest Dermatol 2005;124 (4) Suppl.) A89
86. Grando SA: Acetylcholine receptors in cutaneous biology - receptorology and therapeutic implications. In: Abstracts of the 1st International Meeting on Neurobiology of the Skin, Munster, Germany, February 13-15, 2004, p. 29.
87. Chernyavsky AI, Arredondo J, Marubio LM, Beaudet AL, Vetter DE, Grando SA: Differential regulation of keratinocyte chemokinesis and chemotaxis through distinct nicotinic receptor subtypes. J Invest Dermatol 2004;122 (3) A94 (abstr #559).
88. Grando SA, Chernyavsky AI, Arredondo J: Ability to induce keratinocyte apoptosis determines pathogenicity of pemphigus IgGs. J Invest Dermatol 2004;122 (3) A6 (abstr #35).
89. Arredondo J, Chernyavsky AI, Jolkovsky DL, Marubio LM, Pinkerton KE, Beaudet AL, Grando SA: Nicotine regulates gene expression in oral keratinocytes. J Invest Dermatol 2004;122 (3) A16 (abstr #95).
90. Grando SA: Mucocutaneous cholinergic system is targeted in mustard-induced vesication. In: Abstracts of the 7th Chemical Medical Defense Conference, Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany, April 9-10, 2003.
91. Grando SA, Arredondo J, Chernyavsky A, Pittelkow MR, Kitajima Y, Nguyen VT: Cholinergic stimulation inhibits pemphigus IgG-induced acantholysis and ameliorates clinical disease in a patient with pemphigus vulgaris. J Invest Dermatol 2003;121 (1); abtsr #42.
92. Arredondo J, Hall LL, Nguyen VT, Chernyavsky A, Pinkerton KE, Grando SA: Fibroblast ?3 nicotinic receptor mediates cutaneous effects of tobacco smoke. J Invest Dermatol 2003;121 (1); abstr #223.
93. Grando SA: Role of the cholinergic system in skin biology and pathology. In: Abstracts of the 1st International Workshop on Cutaneous Neuroendocrinology. Hamburg, Germany, September 13-15, 2002.
94. Nguyen VT, Arredondo J, Chernyavsky A, Pittelkow MR, Kitajima Y, Grando SA: Pemphigus vulgaris IgG (PVIgG) and a corticosteroid exhibit reciprocal effects on keratinocyte adhesion molecules. J Invest Dermatol 2002;119:227.
95. Chernyavsky A, Arredondo J, Nguyen VT, Ndoye A, Zia S, Wess J, Grando SA: Molecular mechanisms of stimulatory effect of M4 muscarinic acetylcholine receptor on keratinocyte migration. J Invest Dermatol 2002;119:225.
96. Grando SA, Arredondo J, Chernyavsky A, Kitajima Y, Nguyen VT: Mechanisms of pharmacologic regulation of keratinocyte adhesion by cholinergic drugs. J Invest Dermatol 2002;119:225
97. Arredondo J, Nguyen V, Chernyavsky A, Orr-Urtreger A, Bercovich D, Vetter DE, Beaudet AL, Grando SA: Central role for ?7 nicotinic acetylcholine receptor in terminal differentiation of keratinocytes. J Invest Dermatol 2002;119:249.
98. Grando SA: Biological functions of non-neuronal acetylcholine in mucocutaneous epithelia. In: Non-Neuronal Acetylcholine: Signaling Pathways and Major Biological Effects in Humans. 1st Intl Symp Non-neuronal Acetylcholine, July 6, 2002, San Francisco, CA, p. 18.
99. Bercovich D, Arredondo J, Nguyen VT, Hall LL, Chernyavsky AI, Orr-Urtreger A, Kummer W, Lips K, Vetter DE, Beaudet AL, Grando SA: Nicotinic receptor knockout mice: cholinergic dysfunction in non-neuronal cells. In: Non-Neuronal Acetylcholine: Signaling Pathways and Major Biological Effects in Humans. 1st Intl Symp Non-neuronal Acetylcholine, July 6, 2002, San Francisco, CA, p. 14.
100. Chernyavsky A, Nguyen VT, Arredondo J, Wess J, Grando SA: The m4 muscarinic receptor-selective effects on keratinocyte crawling locomotion. In: Non-Neuronal Acetylcholine: Signaling Pathways and Major Biological Effects in Humans. 1st Intl Symp Non-neuronal Acetylcholine, July 6, 2002, San Francisco, CA, p. 15.
101. Nguyen VT, Arredondo J, Chernyavsky A, Kitajima Y, Grando SA: Keratinocyte acetylcholine receptors regulate cell adhesion. In: Non-Neuronal Acetylcholine: Signaling Pathways and Major Biological Effects in Humans. 1st Intl Symp Non-neuronal Acetylcholine, July 6, 2002, San Francisco, CA, p. 24.
102. Arredondo J, Nguyen VT, Chernyavsky AI, Bercovich D, Orr-Urtreger A, Vetter DE, Beaudet AL, Grando SA: Functional role of ?7 nicotinic receptor in keratinocyte differentiation. In: Non-Neuronal Acetylcholine: Signaling Pathways and Major Biological Effects in Humans. 1st Intl Symp Non-neuronal Acetylcholine, July 6, 2002, San Francisco, CA, p. 14.
103. Grando SA: The importance of non-desmoglein targets of pemphigus autoimmunity. J Invest Dermatol 2002;118:736.
104. Nguyen VT, Grando SA: Novel animal model for testing anti-acantholytic treatments of pemphigus. J Invest Dermatol 2001;117:543.
105. Nguyen VT, Vetter DE, Chernyavsky AI, Elgoyhen AB, Heinemann S, Grando SA: The physiologic control of keratinocyte adhesion involves regulation of cadherin and desmoglein expression via ?9 acetylcholine receptor. J Invest Dermatol 2001;117:396.
106. Arredondo A, Nguyen VT, Chernyavsky AI, Shafii M, Pinkerton KE, Grando SA: Reciprocal changes in the expressions of nicotinic acetylcholine receptors, and the cell cycle and differentiation genes can mediate pathobiologic effects of tobacco products on keratinocytes. J Invest Dermatol 2001;117:478.
107. Nguyen VT, Arredondo J, Chernyavsky AI, Bercovich D, Orr-Urtreger A, Beaudet AL, Grando SA: Abnormalities of keratinocyte functions in the epidermis of knockout mice lacking the neuronal nicotinic acetylcholine receptor subunits ?3, ?7 or ?4. J Invest Dermatol 2001;117:405.
108. Nguyen VT, Ndoye A, Grando SA: Absorption of non-desmoglein antibodies with rDsg-Ig-His helps explain the controversy about immunopathogenesis of pemphigus. J Invest Dermatol 2000;114:845.
109. Buchli R, Ndoye A, Slominski A, Grando SA: Cholinergic control of melanogenesis. J Invest Dermatol 2000;114:859.
110. Hall LL, Buchli R, Ndoye A, Webber RJ, Grando SA: Identification of nicotinic receptors in human skin fibroblasts and study of their role in mediating tobacco-related skin disease. J Invest Dermatol 2000;114:802.
111. Ndoye A, Nguyen VT, Hall LL, Grando SA: Secretion of humectant precursors during the granular cell-corneocyte transition: novel form of keratinocyte apoptosis. J Invest Dermatol 2000;114:796.
112. Nguyen VT, Ndoye A, Grando SA: Pemphigus vulgaris and pemphigus foliaceus IgGs produce distinct disease phenotypes in desmoglein 3 knockout mice. J Invest Dermatol 2000;114:753.
113. Nguyen VT, Ndoye A, Shultz LD, Grando SA: Characterization by immunoprecipitation of non-desmoglein 1 pemphigus vulgaris antibodies causing blisters in desmoglein 3-deficient mice. J Invest Dermatol 1999; 112:531.
114. Buchli R, Ndoye A, Grando SA: Molecular characterization and immunolocalization of muscarinic and nicotinic acetylcholine receptors in human melanocytes. J Invest Dermatol 1999;112:541.
115. Nguyen VT, Ndoye A, Grando SA: A pool of disease-causing pemphigus vulgaris IgGs contains an autoantibody to pemphaxin, a calcium-dependent keratinocyte annexin-like molecule that can be upregulated by methylprednisolone. J Invest Dermatol 1999;112:264.
116. Zia S, Ndoye A, Grando SA: Nicotine reduces keratinocyte migration distance by altering intracellular calcium levels via receptor-mediated pathway. J Invest Dermatol 1999;112:543.
117. Nguyen VT, Bassler KD, Ndoye A, Webber RJ, Shultz LD, Ruben BS, Grando SA: Paraneoplastic pemphigus: a combined humoral and cellular autoimmune disease. J Invest Dermatol 1999;112:568.
118. Ndoye A, Nguyen VT, Zelickson BD, Lawry MA, Grando SA: The upward concentration gradient of free acetylcholine in human epidermis provides for its unopposed secretagouge action in the stratum granulosum: a step toward terminal differentiation. J Invest Dermatol 1999;112:554.
119. Nguyen VT, Buchli R, Ndoye A, Grando SA. Molecular cloning and partial characterization of novel keratinocyte annexin-like molecule identified by pemphigus vulgaris antibodies. J Invest Dermatol, 1998;110: 486, and J Dermatol Sci, 1998;16 (SUPPL. 1): S14.
120. Nguyen VT, Ndoye A, Shultz LD, Grando SA: Binding of pemphigus antibodies to the epidermis of mice lacking desmoglein 3. J Invest Dermatol, 1998;110: 506, and J Dermatol Sci, 1998;16 (SUPPL. 1): S35.
121. Zia S, Buchli R, Ndoye A, Greenberg BM, Nguyen VT, Grando SA: The m4 keratinocyte muscarinic receptor regulates cell motility and modulates intracellular calcium. J Invest Dermatol, 1998;110: 545, and J Dermatol Sci, 1998;16 (SUPPL. 1): S73.
122. Ndoye A, Buchli R, Greenberg BM, Vu Thuong Nguyen, Lawry MA, Webber R, Grando SA: Localization of muscarinic cholinergic receptor subtypes in human epidermis and keratinocyte cell culture. J Invest Dermatol, 1998;110: 579, and J Dermato Sci, 1998;16 (SUPPL. 1): S107.
123. Buchli R, Ndoye A, Webber R, Grando SA: Identification of m2, m4 and m5 subtypes of muscarinic receptors in human skin fibroblasts. J Invest Dermatol, 1998;110:607, and J Dermatology Sci, 1998;16 (SUPPL. 1): S136.
124. Grando SA, Lee TX, Dahl MV: Antibodies to keratinocyte cholinergic receptor in pemphigus. J Invest Dermatol, 1997;108:560.
125. Horton RM, Thuong Nguyen V, Grando SA: Survey of cholinergic receptor types expressed in cultured human keratinocytes. J Invest Dermatol, 1997;108:603.
126. Horton RM, Lee TX, Grando SA: Cloning of the human alpha-9 AChR subunit from normal epidermis and investigations into its physiological role. FASEB J, 1996;10:A688
127. Lee TX, Horton RM, Grando SA: Cholinergic drugs stimulate chemokinesis of human epidermal keratinocytes. J Invest Dermatol, 1996;106:841.
128. Grando SA, Mauro T, Lee TX, Mirfakhraie K, Horton RM: Novel human ?9 acetylcholine receptor subunit, and other new members of the epidermal acetylcholine receptor family. J Invest Dermatol, 1996;106:834.
129. Weinshenker D, Mauro T, Zelickson BD, Kist DA, Dahl MV, Grando SA: A unique pharmacologic profile of the muscarinic acetylcholine receptor of human epidermal keratinocytes. J Invest Dermatol, 1995;104:657.
130. Grando SA, Mauro T: Acetylcholine controls transmembrane calcium transport in human keratinocytes. J Invest Dermatol, 1995;104:592.
131. Pereira EFR, Albuquerque EX, George PG, Horton RM, Conti-Tronconi BM, Grando SA: Neuronal nicotinic receptors expressed in keratinocytes control cell adhesion and motility and are targeted by pemphigus antibodies. (24th Annual Meeting of the Society for Neuroscience, Miami Beach, Florida) Society for Neuroscience Abstracts 1994; 20:1140.
132. Grando SA, George PM, Dahl MV, Conti-Tronconi BM: Antibody against keratinocyte nicotinic acetylcholine receptor in patient with coexistent pemphigus foliaceus, myasthenia gravis and thymoma. J Invest Dermatol, 1994;102:609.
133. Grando SA, Horton RM, Pereira ER, Zelickson BD, Albuquerque EX, Conti-Tronconi BM: Nicotinic acetylcholine receptors expressed in human keratinocytes: pharmacological, functional, and structural characterization J Invest Dermatol, 1994;102:595.
134. Zachary CB, Skubitz APN, Schofield OMV, Kist DA, Grando SA: Polyclonal antisera to an immortal basal cell line recognize ectodermally-derived structures in human skin. Clin Res, 1993;41:664.
135. Grando SA, Zelickson BD, Bigliardi PL, Conti-Tronconi BM: Nicotinic properties of keratinocyte cholinergic receptors. Clin Res, 1993;41:690
136. Schofield OMV, Kist DA, Skubitz APN, Zachary CB, Grando SA: Nodular basal cell carcinoma cell lines: Morphology, Immunophenotype and biosynthetic activity. J Invest Dermatol, 1993;101:439.
137. Grando SA, Bigliardi PL, Zelickson BD, Dahl MV: Location and character of keratinocyte muscarinic receptors. J Invest Dermatol, 1993;101:397.
138. Zachary CB, Schofield OMV, Kist D, Grando SA: Culture of basal cell carcinoma. J Invest Dermatol, 1993;100:602.
139. Grando SA, Bigliardi PL, Dahl MV: Separation and partial characterization of keratinocyte muscarinic acetylcholine receptors. J Invest Dermatol, 1993;100:591.
140. Crosby AM, Grando SA, Dahl MV: Agarose gel keratinocyte outgrowth system as a model of epidermal epithelization. J Invest Dermatol, 1993;100:585.
141. Grando SA, Dahl MV: Biological functions of the keratinocyte cholinergic system. J Invest Dermatol, 1993;100:579.
142. Grando SA, Lynch PJ: Muscarinic antagonist protects keratinocyte monolayers from morphological transformations induced by enalapril, and thiol drugs. J Invest Dermatol, 1993;100:541.
143. Grando SA, Kist DA, Qi M, Dahl MV: Human keratinocytes synthesize and release acetylcholine, a mediator with autocrine function. Clin Res, 1992;40:708.
144. Grando SA, Dahl MV, Bigliardi PL, Hostager BS, Herron MJ, Nelson RD: A putative muscarinic acetylcholine receptor of human epidermal keratinocytes controls cell-cell attachment and motility in vitro. Clin Res, 1992;40:450 and J Invest Dermatol, 1992;98:588.
145. Dahl MV, Grando SA: Acetylcholine antagonizes the effects of pemphigus antibody in epidermal keratinocyte cultures. Clin Res, 1992;40:449 and J Invest Dermatol, 1992;98:588.
146. Grando SA: Shedding snake serum protein interacts with epidermal keratinocytes. Clin Res, 1991;139:739.
147. Grando SA: Shedding snake serum contains cytokine stimulating the expression of pemphigus antigen. J Interferon Res, 1990;10:172.
148. Grando SA, Glukhenky B, Romanenko A, Kutsenko N, Lastovetskaya GI, Barabash T, Kurchenko A, Korostash T, Zhukovsky V, Chernyavsky A: Decompensation of endoproteinase-inhibitor system in pemphigus vulgaris and bullous pemphigoid patients. Thromb Haemost, 1989;62:67.
149. Grando SA, Glukhenky BT: Mediators of immunity in pemphigus and pemphigoid blister fluid. J Invest Dermatol, 1989;93:552.
150. Grando SA: Soluble putative factor of epidermal origin in pemphigus and pemphigoid inhibits interleukin cascade reactions. J Invest Dermatol, 1989;93:552.
151. Grando SA: Shedding snake serum protein (SSSP) causes expression of pemphigus vulgaris antigen in snake epidermis. J Invest Dermatol, 1989;93:300.
152. Nikolaev VG, Glukhenky BT, Chayun OA, Grando SA: Immunomodulating effect of hemosorption followed by cytostatic therapy. In: Abstracts of the YI Annual Meeting of the International Society of Blood Purification, Vicenza, 1988, p. 1.
153. Grando SA, Drannik GN, Kostromin AP, Korostash TA: Exocytosis of serine proteinases from autologous effector and target cells obtained from pemphigus vulgaris patients. In: Abstracts of the IV International Congress of Cell Biology, Ottawa: National Research Council, 1988, p. 236.
154. Grando SA, Glukhenky BT, Romanenko AB, Demidov SV: Pemphigus antibody induced intercellular separation of cultivated murine epidermocytes is accompanied by change in ratio of intraepidermocytic cAMP/cGMP. In: Abstracts of the IV International Congress of Cell Biology, Ottawa: National Research Council, 1988, p. 69.
155. Grando SA, Glukhenky BT: Treatment of pemphigus and pemphigoid patients with combined hemocarboadsorption followed by immunosuppressive therapy. In: Abstracts of the Combined Conference of International Society of Dermatology with the International Society of Dermatopathology. Dermatology in the Developing World, Oxford, 1988, pp. 68-69
156. Glukhenky BT, Grando SA, Kutsenko NS, Lastovetskaya GI, Boiko YY, Barabash TM: Effect of hemosorption on the activity of immunocompetent cells from patients with bullous dermatoses. In: Proceedings of the YI All-Russia Congress on Dermato-Venereology, (Moscow), 1989, p. 420. (In Russian).
157. Glukhenky BT, Grando SA, Korostash TA, Chernyavsky AI, Makarov AV, Chayun OA: Interleukins 1 and in patients with pemphigus and pemphigoid. In: Proceedings of the Annual Scientific & Practical Conference of Kharkhov Regional Dermato-Venereologic Hospital, (Kharkhov), 1988, p. 26. (In Russian).
158. Grando SA, Glukhenky BT, Romanenko AB, Boyko YY, Kutsenko NS, Lastovetskaya GI: Leukotrienes and prostaglandins in bullous dermatoses. In: Proceedings of the Annual Scientific & Practical Conference of Kharkhov Regional Dermato-Venereologic Hospital, (Kharkhov), 1988, p. 25. (In Russian).
159. Glukhenky BT, Grando SA, Kutsenko NS, Lastovetskaya GI, Boyko YY, Barabash TM, Gajduk IV, Korostash TA: Treatment of patients with autoimmune bullous dermatoses by means of eicosanoid metabolism correction. In: Proceedings of the 1st Kyiv Municipal Scientific Conference for Inventors in Medicine, (Kyiv), 1988, Vol. 1, p. 40. (In Russian).
160. Grando SA, The normalization of interleukin cascade reactions due to combined hemocarboperfusion i the course of treatment of pemphigus and pemphigoid. In: Proceedings of the 1st Kyiv Municipal Scientific Conference for Inventors in Medicine, (Kyiv), 1988, Vol. 1, p. 33. (In Russian).
161. Grando SA, Glukhenky BT, Kutsenko NS, Boyko YY, Lastovetskaya GI, Barabash TM: The increase of anti-epidermal-cell autoantibodies in the serum of healthy people in old age. In: Proceedings of the Y All-Union Congress on Gerontology and Geriatrics, (Kyiv), 1988, Vol. 1, p. 168. (In Russian).
162. Glukhenky BT, Grando SA, Kostromin AP, Demidov SV, Chernyavsky AI, Makarov AV, Korostash TA: Cytotoxicity of peripheral blood mononuclear cells from elderly people against autologous epidermal keratinocytes. In: Proceedings of the Y All-Union Congress on Gerontology and Geriatrics, 13 (Kyiv), 1988, Vol. 1, p. 154. (In Russian).
163. Demidov SV, Kostromin AP, Khrapunov SN, Borovok MI, Kujbeda BB, Grando SA: The effect of thymus-derived preparations on the proliferation, cytotoxicity and activity of cyclic nucleotide anabolism and catabolism enzymes in spleen lymphocytes under condition of BCG vaccination. In: Proceedings of the International Workshop on Mathematical Modeling in Immunology and Medicine, (Kyiv), 1988, p. 27. (In Russian).
164. Grando SA, Makarov AV, Kostromin AP, Demidov SV: Pathogenetic grounds for immunosuppressive therapy of patients with autoimmune bullous dermatoses. In: Proceedings of the Y Ukrainian Congress on Dermato-Venereology, (Kharkhov), 1986, p. 95. (In Russian).
165. Glukhenky BT, Lastovetskaya GI, Kalyuzhnaya LD, Kutsenko NS, Kozij LM, Boiko YY, Grando SA, Choban VI: The results of the study of immune system and liver function in patients with secondary syphilis. Clinical and laboratory follow up study. In: Proceedings of the YIII All-Union Congress on Dermato-Venereology, (Moscow), 1985, Vol. 2, p. 351. (In Russian).
166. Grando SA: The use of proteinase inhibitors in atopic dermatitis. In: Proceedings of the YIII All-Union Congress on Dermato-Venereology, (Moscow), 1985, Vol. 1, p. 62. (In Russian).
167. Kurchenko AI, Grando SA: Thymogen immunocorrection in treatment of patients with eczema. In: Current Problems of Scientific and Practical Dermato-Venereology, (Dnepropetrovsk), 1990, pp. 82-83. (In Russian).
168. Glukhenky BT, Boiko YY, Bratys FF, Grando SA: Prostatites as a complication of gonococcal infection. In: Problems in sexopathology and the sexual harmony, (Voroshilovgrad), 1988, pp. 102-103. (In Russian).
169. Glukhenky BT, Grando SA, Glukhenkaya AB: Preliminary results of the combined treatment of patients with atopic dermatitis. In: Proceedings of the Annual Scientific & Practical Conference of Kharkhov Regional Dermato-Venereologic Hospital, (Kharkhov), 1984, p. 14. (In Russian).
170. Grando SA: Gall bladder nerves under condition of experimental gastric rejection. In: Proceedings of the All-Union Scientific Conference on Digestion Physiology and Pathology, (Odessa), 1979, p. 12. (In Russian).
171. Grando SA, Bezdenezhnykh SE, Golota OV: Frequency of chronic non-specific lung diseases among populations of industrial cities. In: Problems in Hygiene and Environment, (Moscow), 1979, p. 66. (In Russian).

Audio Visual
1. Korman NJ, Werth V, Grando S, Sinha A: Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments, MedScape, 12/7/2017) (https://www.medscape.org/viewarticle/883002
2. Grando SA: The role of nicotine in cancer and its impact on therapy, The Video Journal of Oncology, 2016 (http://www.vjoncology.com/video/s2ry8fviaaa-the-role-of-nicotine-in-cancer-and-its-impact-on-therapy).
3. Grando SA: The popularity of e-cigarettes and issues with nicotine. The Video Journal of Oncology, 2016 (http://www.vjoncology.com/video/9nj8llapkyq-the-popularity-of-e-cigarettes-and-issues-with-nicotine).
4. Grando SA: The epidermis and blistering disorders: pemphigus, in Tobin, D.J. (ed.), Skin Biology, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London, 2014, (online at http://hstalks.com/?t=BL1813597-Grando).
5. Grando SA: Smoking and the skin. Dialogues in Dermatology, American Academy of Dermatology, 2011; vol. 67, No.12.
6. Grando SA: Paraneoplastic autoimmune multiorgan syndrome (PAMS). Dialogues in Dermatology, American Academy of Dermatology, 2004; vol 54, No.1
Grants
2021 Allergan Evaluation of Allergan compounds in an in vitro model for sebum production with human sebocyte cells (SEB-1). Amount $124,342
2020 Disimmune Diseases Foundation Development of a bioassay predicting disease relapse in pemphigus vulgaris patients treated with the IVIg- containing multidrug protocol. Amount $75,000
2020 Allergan Evaluation of Allergan compounds in an in vitro model for sebum production with human sebocyte cells (SEB-1). Amount $113,686
2019 Disimmune Diseases Foundation Identification of laboratory parameters predicting the therapeutic response of pemphigus patients to IVIg therapy. Amount $75,000
2019 Allergan Fifth extension of proof-of-concept study of inhibition of sebocyte proliferation and lipid synthesis by AGN compounds'. Amount $113,686
2018-2019 Allergan Fourth extension of proof-of-concept study of inhibition of sebocyte proliferation and lipid synthesis by AGN compounds'. Amount $55,830
2017-2018 Allergan Third extension of proof-of-concept study of inhibition of sebocyte proliferation and lipid synthesis by anti-cholinergic drugs. Amount $85,000
2017-2019 NIH, NCATS/R13 5th International Symposium on Non- neuronal Acetylcholine: From Bench to Bedside. Amount $20,000
2017-2018 Grifols Therapeutics Inc Retrospective analysis of clinical outcome in patients with pemphigus treated with high-dose IVIg adjuvant therapy. Amount $75,000
2016-2017 Allergan Characterization of recombinant $54,075 SLURP-1 and SLURP-2 proteins in corneal epithelial cell culture. Amount $54,075
2016-2017 Allergan Extension of proof-of-concept study of inhibition of sebocyte proliferation and lipid synthesis by anti-cholinergic drugs. Amount $82,843
2016-2017 UC Irvine Elucidating the role of eosinophil degranulation proteins on the basement membrane: Identifying a direct pathogenic mechanism of eosinophils in bullous pemphigoid. Amount $47,000
2015-2016 Allergan Proof-of-concept study of inhibition of sebocyte proliferation and lipid synthesis by anti-cholinergic drugs Amount $50,000
2013-2014 Grifols Therapeutics Inc Proof-Of-Concept Study Of IVIg Efficacy in Patients with Cutaneous Lupus Erythematosus. Amount $219,343
2012-2014 Pfizer Sirolimus For the Treatment of Pemphigus Vulgaris. Free Drug Supply
2012-2014 American Lung Association Nicotinergic Control of Lung Cancer. Amount $200,000
2012-2013 Department of Defense Nicotinic Receptor Polymorphism in Lung Cancer. Amount $115,000
2011-2012 Lung Cancer Research Foundation Potential of Nicotinic Antagonists for Pharmacologic Control of Lung Cancer. Amount $50,000
2010-2015 NIH, NIEHS/R01 Nicotinic Receptor Ligands and Tobacco-Induced Lung Cancer. Amount $1,720,216
2010-2011 NIH, NIAMS/R13 Pemphigus & Pemphigoid: from the bench to the bedside $20,000
2008-2013 NIH, NIDCR/R01 Epithelial Acetylcholine in Oral Biology and Pathology $1,854,317
2007-2010 Institute For Science and Receptor-mediated Mechanisms of Health/Research Grant Tobacco-Induced Lung Oncogenesis $500,000
2006-2009 NIH, NIEHS/R21 Nicotinic receptor-mediated Action of Tobacco Nitrosamines On Bronchial Cells $416,875
2005-2011 NIH, NIGMS/R01 Regulation of Keratinocyte Migration by Acetylcholine $1,687,500
2005-2008 NIH, NCI/R03 Can Nicotinic Antagonists Prevent Tobacco Smoke-induced Lung Tumors in A/J Mice? $151,500
2002-2007 NIH, NIDCR/R01 Epithelial Acetylcholine in Oral Biology and Pathology $1,299,156
2005-2008 Flight Attendant Medical Research Nicotinic Receptors Alter Gene Institute/Research Award Expression in Keratinocytes $324,000
2002-2005 NIH, NIGMS/R01 Regulation of Keratinocyte Migration by Acetylcholine $779,625
2002-2005 Flight Attendant Medical Research Precocious Skin Aging Due to Institute/Research Award Second Hand Smoke $325,500
2002-2005 The Robert Leet & Clara Guthrie Development of Non-steroidal Patterson Trust Treatment of Pemphigus $36,000
1999-2003 Unilever Research/Private Contract Cholinergic Control of Skin Aging $497,369
1998-2001 The Smokeless Tobacco Research The Cholinergic System of Oral Council-USA/Research Grant Epithelium: Structure and Biomedical Significance $278,340
1995-2002 NIH, NIAMS/R29 Cholinergic Control of Keratinocyte Migration $499,528
1996-1999 Unilever Research/Private Contract Cholinergic Networks of Young vs. Aged and Photodamaged vs. Non- photodamaged Skin $465,450
1996-1999 Unilever Research/Private Contract Cholinergic Networks of Young vs. Aged and Photodamaged vs. Non- photodamaged Skin $465,450
1994-1995 Minnesota Medical Physiological and Pathological Foundation/Research Grant Significance of Keratinocyte Cholinergic Receptors $17,500
1992-1993 Dermatology Foundation/Research Subtypes of Cutaneous Muscarinic Grant Receptors $10,000
1992-1993 University of Minnesota Graduate Biological Functions of School/Research Grant Keratinocyte Cholinergic System $8,500
1991-1992 Minnesota Medical Keratinocyte Cholinergic System $7,500
2022 Disimmune Diseases Foundation Elucidation of mechanism of action of autoantibody to M3 muscarinic acetylcholine receptor that predicts disease relapse in pemphigus vulgaris patients treated with the IVIg-containing multidrug protocol. Amount $75,000
2023 Dysimmune Diseases Foundation Characterization of the cellular and molecular mechanisms whereby m3 muscarinic acetylcholine receptor controls epidermal structure and function. Amount $100,000
2021 Dysimmune Diseases Foundation Development of a bioassay predicting disease relapse in pemphigus vulgaris patients treated with the IVIg-containing multidrug protocol - The second yard extension. Amount $75,000
Professional Societies
2020 – Present: American Medical Association
2011 – Present: American Association for Cancer Research
2008 – Present: Panamerican Society for Pigment Cell Researc
2004 – Present: International Society of Dermatology
2004 – Present: American College of Physicians
2003 – 2007 American Society for Biochemistry and Molecular
2001 – 2015: Medical Dermatology Society
1998 – Present: Fellow of the American Academy of Dermatolog
1996 – 2007: Sacramento Valley Dermatological Society
1995 – Present: Ukrainian Medical Association of North Ameri
1993 – 2018: Dermatology Foundation (Leaders Society)
1993 – Present: The Society for Investigative Dermatology
1980 – Present: Ukrainian Association of Dermatologists
Other Experience
Member
UC Irvine Institute for Immunology 2007—pres
Member
UC Irvine Cancer Center & Research Institute 2007—pres
Director
The Immunobullous Clinic, UCI Dermatology 2001—pres
Member
Research Award Nominations Committee, UC Irvine 2021—Pres
Clinical Advisor
American Academy of Dermatology, Burden of Skin Disease Work Group 2016—Pres
Member & Ad Hoc Chair
Academic Resources Advisory Committee, UC Irvine 2011—Pres
Graduate Programs
Dermatology
Immunology and Pathogenesis
Medicinal Chemistry and Pharmacology
Research Centers
UC Irvine, Medical Surge II, Room 362
Last updated
06/20/2023